

Title: Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials

Author names: K. Ryan Wessells, Charles D. Arnold, Christine P. Stewart, Elizabeth L. Prado, Souheila Abbeddou, Seth Adu-Afarwuah, Benjamin F. Arnold, Per Ashorn, Ulla Ashorn, Elodie Becquey, Kenneth H. Brown, Kendra A. Byrd, Rebecca K. Campbell, Parul Christian, Lia C.H. Fernald, Yue-Mei Fan, Emanuela Galasso, Sonja Y. Hess, Lieven Huybregts, Josh M. Jorgensen, Marion Kiprotich, Emma Kortekangas, Anna Lartey, Agnes Le Port, Jef L. Leroy, Audrie Lin, Kenneth Maleta, Susana L. Matias, Mduduzi NN Mbuya, Malay K. Mridha, Kuda Mutasa, Abu Mohd. Naser, Rina R. Paul, Harriet Okronipa, Jean-Bosco Ouédraogo, Amy J. Pickering, Mahbubur Rahman, Kerry Schulze, Laura E. Smith, Ann M. Weber, Amanda Zongrone, Kathryn G. Dewey

Author affiliations:

Institute for Global Nutrition and Department of Nutrition, University of California, Davis, Davis, CA, USA (KRW, CDA, CPS, ELP, KHB, SYH, KGD)

Public Health Nutrition, Department of Public Health and Primary Care, University of Ghent, Ghent, 9000 Belgium (SA)

Department of Nutrition and Food Science, University of Ghana, Legon, Accra, Ghana (SAA, ALartey)

Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA (BFA)

Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland (PA, UA, YMF, EK)

Department of Paediatrics, Tampere University Hospital, Tampere, Finland (PA)

Poverty, Health, and Nutrition Division, International Food Policy Research Institute, 1201 I Street NW, Washington, DC, 20005, USA (EB, LH, JL)

Helen Keller International, New York, NY, USA (KHB)

WorldFish, Bayan Lepas, Penang, Malaysia (KAB)

Division of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, IL, USA (RKC)

Program in Human Nutrition, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA (PC, KS)

School of Public Health, University of California, Berkeley, Berkeley, CA, USA (LCHF, ALin)

Development Research Group, World Bank, Washington DC, USA (EG)

Nutrition Program, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA (JMJ)

One Acre Fund, Nairobi, Kenya (MK)

Independent consultant, Dakar, Senegal (ALP)

Department of Public Health, School of Public Health and Family Medicine, College of Medicine, University of Malawi, Blantyre, Malawi (KMaleta)

Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA, USA (SLM)

Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe (KMutasa, MNNM)

Global Alliance for Improved Nutrition, Washington, DC, USA (MNNM)

Center for Non-communicable Diseases and Nutrition, BRAC James P Grant School of Public Health, Bangladesh (MKM, RRP)

International Center for Diarrheal Diseases Research, Bangladesh (icddr,b) (AMN, MR)

Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA (AMN)

Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, USA (HO)

Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso (JBO)

School of Engineering, Tufts University, Medford, MA, USA (AJPickering)

School of Public Health and Health Professions, Department of Epidemiology and Environmental Health, The State University of New York at Buffalo, NY, USA (LES)

School of Community Health Sciences, Division of Epidemiology, University of Nevada, Reno, USA (AMW)

Independent Consultant, Washington, DC, USA (AZ)

Corresponding Author: K. Ryan Wessells, Department of Nutrition, University of California, One Shields Ave., Davis, CA 95616; 530 400 3097; krwessells@ucdavis.edu

Sources of Support: Bill & Melinda Gates Foundation OPP49817

Short running head: Child SQ-LNS and micronutrient status

Abbreviations: AGP, α -1-acid glycoprotein; BMI, body-mass index; CRP, C-reactive protein; GMR, geometric means ratio; Hb, hemoglobin; IPD, individual participant data; LNS, lipid-based nutrient supplement; MD, mean difference; MN, micronutrient; MNP, multiple micronutrient powder; MQ-LNS, medium-quantity lipid-based nutrient supplements; MUAC, mid-upper arm circumference; PD, prevalence difference; pF, plasma ferritin; PR, prevalence ratio; pZn, plasma zinc; RBP, retinol binding protein; RCT, randomized controlled trial; SES, socio-economic status; SQ-LNS, small-quantity lipid-based nutrient supplements; sTfR, soluble transferrin receptor; WASH, water sanitation and hygiene; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score; ZPP, zinc protoporphyrin

Registry and registry number for systematic reviews or meta-analyses: Registered at

www.crd.york.ac.uk/PROSPERO as CRD42020156663.

Data described in the manuscript, code book, and analytic code will not be made available because they are compiled from 13 different trials, and access is under the control of the investigators of each of those trials.

Parul Christian is a member of the Journal's Editorial Board.

1 **ABSTRACT**

2 **Background:** Small-quantity lipid-based nutrient supplements (SQ-LNS) have been shown to
3 reduce the prevalence of anemia and iron deficiency among infants and young children, but
4 effects on other micronutrients are less well known. Identifying subgroups who may experience
5 greater benefits from SQ-LNS, or who are more likely to respond to the intervention, may
6 facilitate the development of public health policies and programs.

7
8 **Objective:** Our objective was to identify study-level and individual-level modifiers of the effect
9 of SQ-LNS on child hematological and micronutrient status outcomes.

10
11 **Methods:** We conducted a two-stage meta-analysis of individual participant data from 13
12 randomized controlled trials of SQ-LNS provided to children 6 to 24 months of age in low- and
13 middle-income countries (n = 15,946). Outcomes were hemoglobin (Hb), inflammation-adjusted
14 plasma ferritin, soluble transferrin receptor, zinc, retinol and retinol binding protein (RBP), and
15 erythrocyte zinc protoporphyrin, and respective dichotomous outcomes indicative of anemia and
16 micronutrient deficiency. We generated study-specific estimates of SQ-LNS vs. control,
17 including main effects and subgroup estimates for individual-level effect modifiers, and pooled
18 the estimates using fixed-effects models. We used random effects meta-regression to examine
19 potential study-level effect modifiers.

20
21 **Results:** Provision of SQ-LNS decreased the prevalence of anemia (Hb < 110 g/L) by 16%
22 (relative reduction), iron deficiency (plasma ferritin < 12 µg/L) by 56% and iron deficiency
23 anemia (IDA; Hb < 110 g/L and plasma ferritin < 12 µg/L) by 64%. We observed positive

24 effects of SQ-LNS on hematological and iron status outcomes within all subgroups of the study-
25 level and individual-level effect modifiers, but effects were larger in certain subgroups. For
26 example, effects of SQ-LNS on anemia and iron status were greater in trials that provided SQ-
27 LNS for > 12 months and provided 9 mg/d vs. < 9 mg iron/d, and among later-born (vs. first-
28 born) children. There was no effect of SQ-LNS on plasma zinc or retinol, but there was a 7%
29 increase in plasma RBP and a 56% reduction in vitamin A deficiency (RBP < 0.70 μ mol/L), with
30 little evidence of effect modification by individual-level characteristics.

31

32 **Conclusions:** SQ-LNS provided to infants and young children 6-24 months of age can
33 substantially reduce the prevalence of anemia, iron deficiency, and IDA across a range of
34 individual, population and study design characteristics. Policy-makers and program planners
35 should consider SQ-LNS within intervention packages to prevent anemia and iron deficiency.
36 This study was registered at www.crd.york.ac.uk/PROSPERO as CRD42020156663.

37

38 **Keywords:** anemia, iron deficiency, micronutrient status, child undernutrition, complementary
39 feeding, nutrient supplements, home fortification

40 **Introduction**

41 Micronutrient deficiencies are estimated to affect two billion people globally (1, 2) and
42 roughly one-third of the world's population is anemic (3). Infants and young children in low- and
43 middle-income countries are particularly vulnerable to micronutrient undernutrition, owing in
44 part to low micronutrient stores at birth, inadequate dietary intake of bioavailable micronutrients,
45 and increased micronutrient requirements due to infection or malabsorption (4, 5). Deficiencies
46 of iron, zinc, and vitamin A in these populations are associated with increased morbidity and
47 mortality and delayed psychomotor and neurocognitive development (1).

48 Nutritional strategies to prevent micronutrient deficiencies include dietary diversification
49 and modification, provision of supplements, fortification (i.e. large-scale food fortification,
50 biofortification and targeted in-home fortification), and supplemental feeding (e.g., fortified
51 blended foods and lipid-based nutrient supplements). Small-quantity lipid-based nutrient
52 supplements (SQ-LNS) have been designed to prevent malnutrition and provide multiple
53 micronutrients embedded in a food base that also provides energy (100-120 kcal/d), protein and
54 essential fatty acids. This combination of macro- and micro-nutrients in SQ-LNS has the
55 potential to address multiple nutritional deficiencies simultaneously, thus reducing undernutrition
56 (6).

57 A 2019 Cochrane Systematic Review and meta-analysis showed that SQ- and medium-
58 quantity LNS (MQ-LNS) (~125 – 250 kcal/d) given during the period of complementary feeding
59 (6-24 months) significantly reduced the prevalence of anemia by 21% (RR 0.79, 95% CI 0.69 to
60 0.90; 5 studies; anemia as defined by trialists) compared to no intervention (7). Similarly, a 2020
61 meta-analysis demonstrated a 16% reduction in the prevalence of anemia (RR 0.84, 95% CI 0.75,
62 0.93; 8 studies; anemia as defined by trialists) among children who received SQ- or MQ-LNS in
63 comparison to a control group (8). To-date, no meta-analysis has assessed the impact of SQ-LNS

64 provided during the period of complementary feeding on the micronutrient status of infants and
65 young children. However, individual studies have demonstrated significant reductions in the
66 prevalence of iron deficiency and iron deficiency anemia (9-16), although there is heterogeneity
67 in the magnitude of effects. Some, but not all, studies have shown significant improvements in
68 vitamin A, B12 and folate status (11-13, 15, 17); no studies have reported an effect of SQ-LNS
69 on zinc status (9, 11, 15).

70 Differences in study design and context and characteristics of study participants may
71 modify the effect of SQ-LNS on anemia and biomarkers of micronutrient status. The
72 identification of subgroups of infants and young children who experience greater benefits from
73 SQ-LNS, or who are more likely to respond to the intervention, is useful in informing the
74 development of public health policies and programs (18). Thus, we conducted an individual
75 participant data (IPD) meta-analysis of randomized controlled trials (RCTs) of SQ-LNS provided
76 to infants and young children 6 to 24 months of age. The objectives of this analysis were to (1)
77 generate pooled estimates of the effects of SQ-LNS provided to infants and young children 6 to
78 24 months of age on hemoglobin concentration and selected biomarkers of micronutrient status,
79 and (2) identify study- and individual-level modifiers of the effect of SQ-LNS on these outcomes
80 in the same populations. Two companion articles report results for other outcome domains,
81 growth (19) and development (20), from the same IPD meta-analysis.

82

83 **Methods**

84

85 Methods broadly followed those presented in a companion article (19). This systematic
86 review and IPD meta-analysis was pre-registered through PROSPERO (CRD42020156663) (21).

87 A detailed protocol and statistical analysis plan were developed prior to analyses and are

88 available online (22), and we have reported results according to PRISMA-IPD guidelines (23).
89 The analyses were approved by the institutional review board of the University of California,
90 Davis (1463609-1). All individual trial protocols were approved by their relevant institutional
91 ethics committees.

92

93 *Inclusion and exclusion criteria for this systematic review and IPD meta-analysis*

94 Trials were eligible for inclusion if they were individual or cluster RCTs with either
95 longitudinal follow-up or repeated cross-sectional data collection, were conducted in low- or
96 middle-income countries (24), provided SQ-LNS (< ~125 kcal/d) to study participants for at least
97 three months during any part of the age range between 6-24 months of age, and reported at least
98 one outcome of interest.

99 We excluded trials in which SQ-LNS was used for the treatment, not prevention, of
100 malnutrition (i.e., only children with moderate to severe malnutrition were eligible to
101 participate), as well as studies specifically conducted in hospitalized populations or among
102 children with a pre-existing disease. Trials were excluded if the only available comparison group
103 received other types of non-LNS child supplementation (e.g., multiple micronutrient powder,
104 fortified blended food) or if SQ-LNS provision was combined with an additional supplemental
105 food or nutrients within a single arm (e.g., SQ-LNS + food rations vs. control), and there was no
106 appropriate comparison group that would allow isolation of the SQ-LNS effect (e.g., food rations
107 alone).

108 Trials in which there were multiple relevant SQ-LNS interventions (e.g., varying dosages
109 or formulations of SQ-LNS in different arms), or that combined provision of SQ-LNS with other
110 non-nutritional interventions (e.g., water, sanitation and hygiene (WASH)), were eligible for

111 inclusion. In such trials, all arms that provided SQ-LNS were combined into one group, and all
112 non-LNS arms were combined into a single comparison group for each trial (herein labeled
113 “Control”), excluding intervention arms that received non-LNS child supplementation (e.g.,
114 multiple micronutrient powder, fortified-blended food). We also conducted a sensitivity analysis
115 restricting the comparison to specified contrasts of intervention arms within multiple intervention
116 trials (see below).

117 Individual children were included in the analyses if their age at baseline allowed them to
118 receive at least three months of intervention (supplementation or control group components)
119 between 6 and 24 months of age, and if biochemical outcome assessment occurred within 3
120 months of the intended, trial-defined end of supplementation.

121

122 *Search methods and identification of studies*

123 We identified potential studies for inclusion in the IPD analysis from a recent systematic
124 review and meta-analysis of LNS (7). We then repeated the database search strategy employed
125 by Das *et al.*(7), using the same keyword and controlled vocabulary search terms, to capture
126 additional studies (both completed and on-going) indexed in one of 23 international or regional
127 electronic databases and 2 trial registers between July 1, 2018 and May 1, 2019 (*see*

128 ***Supplemental Methods***). One of the authors (KRW) reviewed the titles and abstracts of all
129 studies included in the 2019 Cochrane review, as well as the additional studies identified by the
130 repeated search strategy, to select all potentially relevant studies for full text review. The full-text
131 reports of all potentially relevant records were reviewed. Trials were assessed against the
132 inclusion and exclusion criteria detailed above. In September 2019, the same author reviewed the
133 previously identified on-going studies that met inclusion and exclusion criteria to determine if
134 results for outcomes of interest had been subsequently published.

135

136 *Data collection and harmonization*

137 We invited all principal investigators of eligible studies to participate in this IPD meta-
138 analysis. Individual investigators were asked to provide de-identified individual participant data
139 (primary data) for pre-specified variables (defined above and detailed in a data dictionary
140 provided to investigators). The IPD analyst (CDA) collected and managed the individual
141 participant data, and communicated with investigators to request any missing variables or other
142 information.

143

144 *IPD integrity*

145 We conducted a complete-case, intention to treat analysis (25). We checked data for
146 completeness by crosschecking sample sizes with study protocols and publications. We also
147 crosschecked the data provided against reported values for each trial to ensure consistency.
148 Variables were assessed for outliers and low frequency categories. Relevant model assumptions
149 were assessed (e.g. Shapiro-Wilk normality testing and Breusch-Pagan heteroscedasticity
150 testing) and outcome variables were appropriately transformed before subsequent analyses, as
151 necessary.

152

153 *Assessment of risk of bias in each study and quality of evidence across studies*

154 Two independent reviewers (KRW and CDA) assessed risk of bias using the criteria
155 outlined in the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (26).
156 We assessed each trial against the following criteria: random sequence generation and allocation
157 concealment (selection bias), blinding of participants and personnel (performance bias), blinding
158 of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective

159 reporting (reporting bias), and other sources of bias. Reviewers also assessed the quality of
160 evidence for each primary and secondary outcome across all trials based on the five GRADE
161 criteria: risk of bias, inconsistency of effect, imprecision, indirectness and publication bias (27).
162 Any discrepancies were resolved by discussion or consultation with the core working group, as
163 needed.

164
165 *Specification of outcomes and effect measures*

166
167 We specified outcomes *a priori* in the statistical analysis plan (22). Outcomes of interest
168 are listed in **Box 1**. For the estimation of the main effects, we pre-specified hemoglobin
169 concentration, anemia, moderate-to-severe anemia, and biomarkers of iron status as primary
170 outcomes in the statistical analysis plan, and present results for all outcomes. Hemoglobin
171 concentrations were adjusted for altitude, as necessary (28). Ferritin, sTfR, ZPP, zinc, retinol and
172 RBP concentrations were adjusted for inflammation (i.e., C-reactive protein (CRP) and/or α -1-
173 acid glycoprotein (AGP) concentrations, as available), using a regression correction approach
174 adapted from the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia
175 (BRINDA) project and described in detail elsewhere (29); results are presented for
176 inflammation-adjusted concentrations.

177 The principal measure of effect for normally distributed continuous outcomes was the
178 mean difference (MD) between the intervention and comparison groups at endline, defined as the
179 principal post-intervention time point as reported by each longitudinal trial or at an age closest to
180 the end of the supplementation period for cross-sectional samples. For natural log transformed
181 outcomes, the principal measure of effect was the ratio of geometric means (GMR) between the
182 two groups at endline. For binary outcomes, the principal measure of effect was the prevalence
183 ratio (PR; relative difference in proportions between groups) at endline. We also estimated

184 prevalence differences (PD; in absolute percentage points) but considered them as secondary
185 assessments of binary outcomes because such estimates are less consistent than prevalence ratios
186 (26).

187 The treatment comparison of interest was child SQ-LNS vs. control. In the intervention
188 groups, child SQ-LNS may have been provided along with other nutrition-sensitive co-
189 interventions (e.g., WASH or child morbidity monitoring and treatment). The control groups
190 consisted of passive or active comparison arms which provided no intervention or an
191 intervention without any type of LNS or other child supplement (e.g., WASH). Several trials (or
192 arms within trials) have delivered SQ-LNS to children whose mothers received maternal SQ-
193 LNS during pregnancy and postpartum. We had originally planned to include trial arms that
194 provided both maternal and child SQ-LNS in a sensitivity analysis only (i.e., the all-trials
195 analysis), as maternal supplementation may have an additive effect on child outcomes when SQ-
196 LNS is provided to both mothers and to their children. However, to maximize study inclusion
197 and participant sample size, we decided post-hoc that if the main effects did not differ between
198 the child-LNS-only analysis and the all-trials analysis (including maternal plus child LNS arms)
199 by more than 20% for mean differences or by more than 0.05 for ratios of geometric means or
200 prevalence ratios, the results of the all-trials analyses would be presented as the principal
201 findings. Two additional sensitivity analyses were also conducted, as described below.

202

203 *Synthesis methods and exploration of variation in effects*

204 We separately investigated: 1) full sample main effects of the intervention, 2) effect
205 modification by study-level characteristics, and 3) effect modification by individual-level
206 characteristics. For all three sets of analyses, we used a two-stage approach, which is preferred
207 when the analysis includes cluster-randomized trials (30). In the first stage, we generated

208 intervention effect estimates within each individual study. For longitudinal studies, we controlled
209 for baseline status of the outcome variable, if available, to gain efficiency. For cluster-
210 randomized trials, we used robust standard errors with randomization clusters as the independent
211 unit (31). In the second stage, we pooled the first stage estimates using inverse-variance
212 weighted fixed effects. We also conducted sensitivity analyses in which we pooled estimates
213 using inverse-variance weighted random effects (32). Pooled estimates were only generated if
214 three or more study or sub-study SQ-LNS vs. control comparisons were available for inclusion in
215 the pooled estimate (e.g., 3 or more comparisons were represented within a study-level effect
216 modification category).

217 1) *Full sample main effects of the intervention:* We first estimated the intervention effect
218 for each study. We then pooled the first stage estimates to generate a pooled point estimate, 95%
219 confidence interval, and corresponding p-value.

220 2) *Effect modification by study level characteristics:* We identified potential study-level
221 effect modifiers prior to receipt of data, and categorized individual studies based on the
222 distribution of effect modifier values across all studies (**Box 2**). We used random effects meta-
223 regression to test the association between each effect modifier and the intervention. In the first
224 stage of analysis, we estimated the parameter corresponding to the intervention effect as
225 described above. In the second stage, we used a bivariate random effects meta-regression to test
226 the association between the study-specific intervention effect and study level characteristics.

227 3) *Effect modification by individual level characteristics:* We identified potential
228 individual-level characteristics based on a comprehensive review of effect modifiers considered
229 by individual trials (either listed *a priori* in statistical analysis plans or as published) or selected
230 based on biological plausibility (**Box 2**). We estimated the parameter corresponding to the

231 interaction term of the effect modifier and the intervention for each study (31), as follows. For
232 categorical effect modifiers, we first recoded them to create binary variables if needed, and then
233 determined the interaction between the intervention and the binary effect modifier. We
234 transformed continuous effect modifiers into binary variables by modeling the relationship
235 within each study using splines and then pooling the first stage estimates to generate a pooled,
236 fitted line. We defined programmatically useful dichotomous cutoffs based on the pooled fitted
237 spline results and relevant context. We then generated pooled intervention effect estimates within
238 each category to determine how the intervention effect in one subgroup differed from the
239 intervention effect in the specified reference subgroup.

240 In all analyses, heterogeneity was assessed using I^2 and Tau^2 statistics, within strata when
241 relevant (33). We used a p-value of < 0.05 for main effects and a p-diff or p-for-interaction $<$
242 0.10 for effect modification by study-level or individual-level characteristics, respectively.
243 Because biochemical outcomes are inter-related and the effect modification analyses are
244 inherently exploratory, we did not adjust for multiple hypothesis testing (34).

245 To aid in interpretation of individual-level effect modification, we evaluated the results
246 for binary outcomes to identify what we will call the “cutoff effect”. The distribution of the
247 continuous outcome relative to the cutoff for the corresponding binary outcome (e.g., distribution
248 of hemoglobin around the 110 g/L anemia cutoff) in the 2 effect modifier subgroups can
249 influence the prevalence ratio and prevalence difference. When the mean in each of the 2
250 subgroups falls in a different location relative to the cutoff, the proportion of children close to the
251 cutoff may be different between subgroups. This can lead to a greater reduction in the adverse
252 binary outcome within one subgroup than within the other even if the shift in the mean value due
253 to SQ-LNS is the same in both subgroups. To examine this, we simulated what would happen if

254 we shifted the distribution of the non-reference effect modification subgroup to align with the
255 reference subgroup (see Box 2), while maintaining the observed intervention effect mean
256 difference in the continuous outcome within each subgroup. Based on ad-hoc, pragmatic criteria,
257 if the p-for-interaction shifted from < 0.1 to > 0.2 , we concluded that the cutoff effect explained
258 the apparent effect modification; if it shifted from < 0.1 to > 0.1 but < 0.2 , we concluded that the
259 cutoff effect partially contributed to the apparent effect modification.

260

261 *Additional sensitivity analyses*

262 For the child SQ-LNS only and all-trials analyses, we combined all non-LNS arms into a
263 ‘Control’ group for that trial. However, substantial variations in trial design (e.g., integration of
264 SQ-LNS supplementation with WASH interventions or enhanced morbidity monitoring and
265 treatment, use of passive vs. active control arms) might influence the effect size of the estimates.
266 Therefore, we conducted sensitivity analyses based on child-LNS only analyses in which we (1)
267 separated the comparisons within trials that contained multi-component arms, thus restricting the
268 comparisons to pairs of arms with the same non-nutrition components (e.g. SQ-LNS+WASH vs.
269 WASH and SQ-LNS vs. control) or (2) excluded passive control arms, i.e., restricting the
270 comparison to SQ-LNS vs. active control arms (**Supplemental Table 1**). These analyses are
271 considered exploratory.

272

273 **Results**

274 *Literature search and trial characteristics*

275 We identified 15 trials that met our inclusion criteria for the child SQ-LNS only and/or
276 all-trials analyses, 13 of which (35-48) provided individual participant biochemical data and are
277 included in this analysis (9-13, 15-17, 39, 46-48) (**Figure 1**). In one study biochemical data were

278 not collected (49), and investigators for one trial were unable to participate (14). An overview of
279 each trial included in the analysis is provided in **Table 1**; additional details are provided in
280 Supplemental Table 1. One trial was designed *a priori* to present results separately for HIV
281 exposed and HIV un-exposed children (47, 48); therefore we considered it herein as two
282 comparisons in all analyses and presentation of results. The PROMIS trials in Burkina Faso and
283 Mali each included a longitudinal cohort and repeated cross-sectional surveys (at baseline and
284 endline); however biochemical samples were collected only in the cross-sectional surveys (39,
285 46).

286 The 13 trials in these analyses were conducted in 9 countries in Sub-Saharan Africa and
287 South Asia, and included a total of 15,946 infants and young children with biochemical data.
288 Eleven trials began child supplementation with SQ-LNS at 6 months of age; for the remaining
289 two trials, SQ-LNS supplementation began when infants were 9 months of age in one (38), and
290 between 6-11 months of age in the other (43). Supplementation occurred for 6 to 18 months in
291 duration, depending on the trial. Four trials included intervention arms that also provided SQ-
292 LNS to mothers during pregnancy and the first 6 months postpartum (36, 41, 43, 44). The
293 majority of trials provided a peanut- and milk-based SQ-LNS providing approximately 120
294 kcal/d and 1 RDA of most micronutrients (**Supplemental Table 2**). However, the iron dose per
295 day varied among trials. Four trials provided 9 mg/d iron (36, 37, 40, 42), 8 trials provided 6
296 mg/d iron (38, 39, 41, 43-48), and one trial provided 3.3 – 9 mg/d iron depending on study arm
297 and child age (35).

298 Categorizations and descriptive information for potential study- and individual-level
299 effect modifiers, by trial, are presented in **Supplemental Tables 3 - 4**, respectively.
300 Characteristics ranged widely across trials. Based on data from national surveys, the prevalence

301 of anemia among children 6-59 months ranged from 36% to 88%, and the prevalence of malaria
302 (presumed and confirmed cases) ranged from < 1% to 59% (50). Based on data from individual
303 trials, the study-level prevalence of elevated CRP ranged from 11% to 34% and the prevalence of
304 elevated AGP ranged from 29% to 68%.

305 All trials measured hemoglobin concentration (n = 15,398), and 11 reported at least one
306 biomarker of iron status (n = 1,542 – 3,078) (Supplemental Table 1, **Supplemental Table 5**).
307 Fewer studies assessed zinc (3 studies; n = 1,133) or vitamin A (9 studies; n = 1,236 – 2,314)
308 status. Assessments of hepcidin, folate and vitamin B12 concentrations were planned in 3-4
309 studies each, but data were not yet available from a sufficient number of trials to be included in
310 the present analysis. Median biomarker concentrations and prevalence of dichotomous study
311 outcomes among control groups by trial are presented in Table 1 (anemia and iron deficiency)
312 and **Supplemental Table 6** (all outcomes). In control groups at endline, the prevalence of
313 anemia ranged from 16% to 91%, the prevalence of iron deficiency ranged from 22% to 59%,
314 and the prevalence of IDA ranged from 9% to 55%.

315 In general, trials were considered to have a low risk of bias, with the exception of lack of
316 masking of participants owing to the nature of the intervention (**Supplemental Table 7** and
317 **Supplemental Figure 1**).

318
319 *Main effects of SQ-LNS on anemia and micronutrient status*

320 Results from the all-trials analyses, inclusive of maternal + child SQ-LNS trials/arms, are
321 presented below, and in **Table 2**, because the results from the all-trials and child-LNS-only
322 analyses were similar for all outcomes (**Supplemental Figures 2A to 2D**). Forest plots for all
323 main effects by outcome and individual study are presented below for selected outcomes and as
324 supplemental materials for all other outcomes (**Supplemental Figures 3A to 3AA**).

325 SQ-LNS had a significant positive effect on all biomarkers of hematological and iron
326 status (Table 2, **Figures 2-3**). Compared to control children, hemoglobin concentrations were
327 2.77 g/L higher among children who received SQ-LNS; additionally, ferritin concentrations were
328 56% higher, and sTfR and ZPP concentrations were 17% lower among children who received
329 SQ-LNS vs. control. SQ-LNS reduced the prevalence of anemia by 16% (10 percentage points),
330 iron deficiency by 56% (22 percentage points), and IDA by 64% (14 percentage points).
331 Differences in plasma zinc and retinol concentrations between those who received SQ-LNS and
332 those who did not were not significant. RBP concentrations were 7% higher among children who
333 received SQ-LNS compared to the control group. SQ-LNS reduced the prevalences of low and
334 marginal vitamin A status, as measured by RBP, by 56% (3 percentage points) and 22% (8
335 percentage points), respectively; there was no effect of SQ-LNS on vitamin A status as measured
336 by retinol. We rated the quality of evidence for hemoglobin, ferritin and sTfR concentrations, as
337 well as anemia, moderate-to-severe anemia, iron deficiency, elevated sTfR and IDA as high,
338 based on the GRADE criteria listed above in Methods: at least 6 randomized controlled trials
339 were available for these outcomes and the total sample size was $\sim > 2,500$, the risk of bias was
340 low, all trials were directly aimed at evaluating SQ-LNS, funnel plots revealed no indication of
341 publication bias, and the direction of the effect was consistent even though the magnitude of the
342 effect across trials differed (i.e., moderate to high heterogeneity). For all other outcomes, we
343 rated the quality of the evidence as low to moderate, primarily because of limited availability of
344 data, i.e. fewer trials and participants.

345 Mean differences, ratios of geometric means and prevalence ratios for all outcomes were
346 either identical or greater in random vs. fixed effects models (Supplemental Figures 3A to 3AA).
347 The point estimates of the main effects were similar in the sensitivity analyses in which multi-

348 component arms (e.g. WASH + SQ-LNS) were compared to reference groups that had the same
349 components without SQ-LNS and in which passive control trials were excluded (Supplemental
350 Figures 2A-D). For example, the prevalence ratios for anemia ranged from 0.82-0.84 and those
351 for iron deficiency were 0.36-0.44. There were no differences in statistical significance between
352 models in which outcomes were adjusted vs. not adjusted for inflammation (data not shown).

353

354 *Effect modification by study-level characteristics*

355 The effects of SQ-LNS on hemoglobin, anemia and biomarkers of iron status, stratified
356 by study-level characteristics, are presented in **Figures 4A to 4H**, and an overview of these
357 results is presented in **Table 3**. Forest plots for all outcomes stratified by study-level effect
358 modifiers are presented in **Supplemental Figures 4A to 4AA**. We were unable to generate
359 pooled estimates for effect modification by any study-level characteristics for ZPP and
360 biomarkers of zinc and vitamin A status (i.e., retinol and RBP) due to the limited number of
361 studies that measured these biomarkers. For iron status biomarkers (ferritin and sTfR), water
362 quality and sanitation sub-groups captured the same trials, so these characteristics are considered
363 as a single effect modifier at the study-level. Effect modification results were generally
364 consistent across all sensitivity analyses (**Supplemental Figures 5A to 5AA**) and between
365 models in which outcomes were inflammation-adjusted or not (data not shown); the results
366 presented below refer to the all-trials analyses of inflammation-adjusted outcomes.

367 In all analyses of effect modification by study-level characteristics, the 95% confidence
368 interval of the mean hemoglobin difference, and the ratios of geometric mean ferritin and sTfR
369 concentrations, excluded the null for both strata, indicating that there were significant
370 improvements in hemoglobin, ferritin and sTfR concentrations among children receiving SQ-
371 LNS regardless of study-level characteristics. Similarly, the upper bound of the 95% confidence

372 interval was < 1 for the prevalence ratio and < 0 for the prevalence difference for both categories
373 in all comparisons, indicating that there were significant reductions in the prevalence of anemia,
374 iron deficiency and IDA among children receiving SQ-LNS regardless of study-level
375 characteristics. However, there were some significant interactions, which are described below.

376

377 Hemoglobin concentrations and anemia

378 Reductions in anemia prevalence due to SQ-LNS were greater among studies conducted
379 in South Asia than in Africa (PR: 0.64 vs. 0.81, Figure 4B, Supplemental Figure 4B1). We
380 observed a greater effect of SQ-LNS on hemoglobin concentrations among high anemia burden
381 countries, compared to countries with a moderate burden of anemia (MD: 4.88 g/L vs. 2.49 g/L,
382 Figure 4A, Supplemental Figure 4A2), although the effect of SQ-LNS on anemia prevalence was
383 lower in high anemia burden countries than in moderate anemia burden countries (PR: 0.83 vs.
384 0.75, Figure 4B, Supplemental Figure 4B2). In addition, there was a greater effect of SQ-LNS on
385 the prevalence of anemia among studies conducted in countries with a low vs. high malaria
386 prevalence (PR: 0.73 vs. 0.84, Figure 4B, Supplemental Figure 4B3) and at sites with a low
387 inflammation prevalence compared to those with a higher inflammation prevalence (PR: 0.71 vs.
388 0.87, Figure 4B, Supplemental Figure 4B4). Study-level access to improved sanitation or water
389 quality did not significantly modify the effects of SQ-LNS on hemoglobin concentrations (Figure
390 4A, Supplemental Figures 4A4 and 4A5) or the prevalence of anemia (Figure 4B, Supplemental
391 Figures 4B4 and 4B5).

392 Among studies that provided supplements for longer than 12 months compared to 12
393 months or less, there was a greater effect of SQ-LNS on the prevalence of both anemia (PR: 0.69
394 vs. 0.83, Figure 4B, Supplemental Figure 4B7) and moderate-to-severe anemia (PR: 0.62 vs.

395 0.74, Figure 4C and Supplemental Figure 4D7). Similarly, among studies that provided a higher
396 iron dose (9 mg/d) compared to those providing a lower dose (< 9 mg/d), we observed a greater
397 effect of SQ-LNS on the prevalence of anemia (PR: 0.61 vs. 0.85, Figure 4B, Supplemental
398 Figure 4B8) and moderate-to-severe anemia (PR: 0.52 vs. 0.76, Supplemental Figure 4D8).
399 There was no effect modification by frequency of contact (weekly vs. monthly), but we did
400 observe a greater effect of SQ-LNS on hemoglobin concentrations and the prevalence of anemia
401 among studies that reported high compliance, compared to those reporting lower compliance
402 (MD: 4.78 g/L vs. 2.59 g/L, Figure 4A and Supplemental Figure 4A10 and PR: 0.68 vs. 0.84,
403 Figure 4B and Supplemental Figure 4B10, respectively).

404

405 Biomarkers of iron status and prevalence of deficiency

406 The effect of SQ-LNS on the prevalence of iron deficiency (inflammation-adjusted
407 ferritin concentration < 12 µg/L) was greater among trials conducted in South Asia than in Africa
408 (PR: 0.31 vs. 0.49, Figure 4E and Supplemental Figure 4G1), although the percentage point
409 reduction in iron deficiency associated with SQ-LNS was lower among sites in South Asia (vs.
410 Africa) (18 vs. 30 percentage points; $P = 0.026$, Supplemental Figure 4H1). Study level
411 sanitation and water quality did not significantly modify the effects of SQ-LNS on ferritin or
412 sTfR concentrations or the relative reductions in the prevalences of iron deficiency and high
413 sTfR (Figures 4D-4E, 4G-4H, Supplemental Figures 4F5-6, 4G5-6, 4K5-6, 4L5-6). We did
414 observe greater effects of SQ-LNS on the relative reduction in the prevalence of IDA among
415 trials conducted in sites where a greater proportion of households had access to improved
416 sanitation and water quality, compared to sites with lower sanitation and water quality (PR: 0.20
417 vs. 0.43, Figure 2F, Supplemental Figure 4I5-6), consistent with the non-significant differences

418 in the relative reductions in the prevalence of iron deficiency (PR: 0.38 vs. 0.51; P-for-diff =
419 0.105, Figure 4E, Supplemental Figure 4G6). However, the percentage point reduction in iron
420 deficiency due to SQ-LNS was actually greater among trials conducted in sites where a lower
421 (vs. higher) proportion of households had access to improved sanitation and water quality (28 vs.
422 18 percentage points; P-for-diff = 0.006, Supplemental Figures 4H5-6).

423 We observed a greater effect of SQ-LNS on the prevalence of iron deficiency among
424 studies that provided SQ-LNS for longer than 12 months compared to studies of shorter
425 durations (PR: 0.34 vs. 0.49, Figure 4E, Supplemental Figure 4G7). In addition, we observed a
426 greater effect of SQ-LNS on ferritin concentrations among studies that provided 9 mg/d of iron,
427 compared to studies that provided < 9 mg/d (GMR: 1.67 vs. 1.42, Figure 4D and Supplemental
428 Figure 4F8). Frequency of contact did not significantly modify the effects of SQ-LNS on ferritin
429 or sTfR concentrations, nor on prevalences of iron deficiency or IDA. However, the effect of
430 SQ-LNS on elevated sTfR (indicative of impaired functional iron status) was greater among
431 studies in which children received weekly vs. monthly study visits (PR: 0.46 vs. 0.69, Figure 4H
432 and Supplemental Figure 4L9).

433

434 Overview of study-level effect modification

435 Table 3 shows that numerous characteristics of study context and design (e.g., anemia
436 burden, iron dose, duration of supplementation) modified the effect of SQ-LNS on hematological
437 and iron status biomarkers. When there is no significant effect modification for a continuous
438 outcome (e.g., hemoglobin concentration) but there is for the prevalence ratio or prevalence
439 difference for the corresponding binary outcome (e.g. anemia), the results could be due to the
440 “cutoff effect”, as described in Methods. Our simulations identified several cutoff effects (Table

441 3). For example, we observed greater effects of SQ-LNS on the prevalence of anemia in sites
442 with a moderate (vs. high) burden of anemia, a low (vs. high) malaria burden, and a low (vs.
443 high) inflammation burden, three study-level characteristics that tended to cluster together.
444 However, the effects of SQ-LNS on hemoglobin concentrations were greater in studies with a
445 higher burden of anemia and mean hemoglobin differences due to SQ-LNS did not differ
446 significantly by malaria or inflammation burden. Simulations indicated that the observed effect
447 modification by study-level anemia, malaria and inflammation burden with respect to the
448 prevalence ratio for anemia appears to be due to the cut-off effect (i.e., differences in the
449 population distribution of hemoglobin between sub-groups). Among control group children,
450 mean hemoglobin concentrations were higher in sites with lower burdens of anemia, malaria and
451 inflammation than in sites with higher prevalences of these factors (≈ 114 g/L vs. ≈ 100 g/L). As a
452 result, a greater proportion of children who received SQ-LNS shifted across the cut-off from
453 anemic to non-anemic in the former sites than in the latter. The cutoff effect also appeared to
454 contribute, at least partially, to the apparent effect modification by a) region, for the prevalence
455 of anemia and the prevalence difference for iron deficiency, b) improved sanitation and water
456 quality, for the prevalence of IDA, c) supplementation duration and iron dose, for the prevalence
457 of moderate-to-severe anemia, and d) frequency of contact, for the prevalence of elevated sTfR.

458

459 *Effect modification by individual-level characteristics*

460 The effects of SQ-LNS on hemoglobin (anemia) and biomarkers of iron status, stratified
461 by individual-level (i.e., child, maternal and household) characteristics, are presented in **Figures**
462 **5A-5H** and an overview of individual-level effect modification is provided in **Table 4**. Forest
463 plots of all outcomes by potential individual-level effect modifiers are presented in
464 **Supplemental Figures 6A to 6AA and 7A to 7AA**. For some biomarkers of micronutrient

465 status, we were unable to generate pooled estimates for effect modification by certain potential
466 individual-level effect modifiers because fewer than three trials (comparisons) assessed both the
467 outcome and the effect modifier of interest and/or there were too few individuals with the
468 outcome categorized into each stratum (e.g., ferritin concentration by baseline anemia status or
469 household sanitation). Effect modification results were generally consistent across all sensitivity
470 analyses and between the fixed and random effects models (**Supplemental Figures 8A to 8AA**).
471 Because all-trials analyses maximized the sample size, some potential effect modifiers were
472 significant in the all-trials, but not in the sensitivity analyses. However, the directionality of
473 effect modification was consistent across all analyses. In addition, results were generally
474 consistent between models in which outcomes were inflammation-adjusted or not (data not
475 shown). Thus, the results presented below refer to the fixed effects models for all-trials analyses
476 of inflammation-adjusted outcomes.

477

478 Hemoglobin concentration and prevalence of anemia

479 In general, maternal characteristics did not significantly modify the effect of SQ-LNS on
480 hemoglobin concentration or anemia, with two exceptions: there was a greater absolute reduction
481 in the prevalence of moderate-to-severe anemia (8 vs. 6 percentage points, P-for-interaction =
482 0.047; Supplemental Figure 6E1) among children of mothers with a higher (vs. lower) BMI, and
483 there was a greater effect of SQ-LNS on hemoglobin concentration and anemia prevalence
484 among children of older compared to younger mothers (MD: 3.33 g/L vs. 2.61 g/L and PR: 0.83
485 vs. 0.87, respectively; Figures 5A-B, Supplemental Figures 6A2 and 6B2).

486 Regarding child characteristics, SQ-LNS had a greater effect among later-born vs. first-
487 born children on hemoglobin concentrations (MD: 3.25 g/L vs. 2.28 g/L; Figure 5A,
488 Supplemental Figure 6A5) and the percentage point reduction in the prevalence of anemia (12

489 vs. 7 percentage points; P-for-interaction = 0.024, Supplemental Figure 6C5), although not on
490 the relative reduction in anemia prevalence (Figure 5B, Supplemental Figure 6B5). The effect of
491 SQ-LNS on hemoglobin concentration did not differ by child sex (Figure 5A, Supplemental
492 Figure 6A4) but we observed a greater effect of SQ-LNS on the prevalence of anemia among
493 female vs. male children (PR: 0.82 vs. 0.87; Figure 5B, Supplemental Figure 6B4). SQ-LNS had
494 a greater effect on hemoglobin concentrations, but not the prevalence of anemia, among children
495 who were anemic at baseline (vs. those who were not) (MD: 3.91 g/L vs. 1.63 g/L; Figures 5A
496 and 5B, Supplemental Figures 6A7 and 6B7). The effect of SQ-LNS on hemoglobin
497 concentration did not differ by inflammation status at endline (Figure 5A, Supplemental Figure
498 6A9), however, SQ-LNS had a greater effect on the prevalence of anemia among children
499 without (vs. with) inflammation at endline (PR: 0.66 vs. 0.85; Figure 5B, Supplemental Figure
500 6B9). Child acute malnutrition at baseline and receipt of high-dose vitamin A supplements did
501 not significantly modify the effects of SQ-LNS on hemoglobin concentrations or the prevalence
502 of anemia.

503 Household water quality and sanitation did not significantly modify the effects of SQ-
504 LNS on hemoglobin concentrations (Figure 5A, Supplemental Figure 7A3-4). However, there
505 was a greater effect of SQ-LNS on anemia prevalence among children in households with
506 improved water quality than among children in households with unimproved water quality (PR:
507 0.82 vs. 0.88; Figure 5B, Supplemental Figure 7B3). Conversely, the effects of SQ-LNS on
508 prevalences of anemia and moderate to severe anemia were greater among children in
509 households with unimproved vs. improved sanitation (Figure 5B-C, Supplemental Figures 7B4
510 and 7D4). Socio-economic status (SES), food security, and season of outcome measurement did

511 not significantly modify the effects of SQ-LNS on hemoglobin concentrations or the prevalence
512 of anemia.

513

514 Biomarkers of iron status and prevalence of iron deficiency and iron deficiency anemia

515 In general, maternal characteristics (i.e., BMI, age and education) did not significantly
516 modify the effect of SQ-LNS on iron status biomarkers (i.e., ferritin, sTfR or ZPP), with the
517 exception of a greater absolute reduction in the prevalence of IDA (21 vs. 13 percentage points,
518 P-for-interaction = 0.023; Supplemental Figure 6J1) among children of mothers with a higher
519 (vs. lower) BMI, and greater absolute reductions in the prevalence of elevated ZPP among
520 children of mothers with more (vs. less) formal education (14 vs. 9 percentage points, P-for-
521 interaction = 0.080; Supplemental Figure 6P3).

522 We observed a greater effect of SQ-LNS on ferritin concentrations among later-born
523 children, compared to first-born children (GMR: 1.64 vs. 1.40; Figure 5D and Supplemental
524 Figure 6F5), among children who were acutely malnourished (vs. non-malnourished) at baseline
525 (GMR: 1.85 vs. 1.47; Figure 5D and Supplemental Figure 6F6), and among children without (vs.
526 with) inflammation at endline (GMR: 1.65 vs. 1.48; Figure 5D and Supplemental Figure 6F9). In
527 addition, we observed a greater effect of SQ-LNS on ZPP concentrations in male vs. female
528 children (GMR: 0.76 vs. 0.82; Supplemental Figure 6N4). No individual-level child
529 characteristics modified the effect of SQ-LNS on the prevalence of iron deficiency, elevated
530 sTfR or ZPP, or IDA.

531 Household characteristics (i.e., SES, food security, water quality and sanitation) did not
532 modify the effect of SQ-LNS on ferritin or ZPP concentrations or the prevalence of iron
533 deficiency, elevated ZPP or IDA, with the exception of greater absolute reductions in the

534 prevalence of IDA among children of higher (vs. lower) SES (20 vs. 12 percentage points, P-for-
535 interaction = 0.039; Supplemental Figure 7J1). We observed a greater effect of SQ-LNS on the
536 prevalence of elevated sTfR among children in households with SES above (vs. below) the
537 study-specific median (PR: 0.60 vs. 0.71; Figure 5H, Supplemental Figure 7L1). In addition, SQ-
538 LNS had a greater effect on sTfR concentrations among children in households with improved
539 (vs. unimproved) water quality (GMR: 0.75 vs. 0.82; Figure 5G, Supplemental Figure 7K3).

540 There was a greater effect of SQ-LNS on ferritin concentrations, and the prevalence of
541 iron deficiency, in the rainy season than in the dry season (GMR: 1.74 vs. 1.44; PR: 0.37 vs.
542 0.53; Figure 5D-E, Supplemental Figures 7F6, 7G6). In addition, there was a greater effect of
543 SQ-LNS on ZPP concentrations in the rainy season vs. the dry season, (GMR: 0.76 vs. 0.84;
544 Supplemental Figure 7N6).

545

546 Biomarkers of zinc and vitamin A status

547 The effect of SQ-LNS on plasma zinc concentrations was greater among children of older
548 vs. younger mothers (GMR: 1.03 vs. 0.96; Supplemental Figure 6Q2), and in the rainy season as
549 compared to the dry season (GMR: 1.02 vs. 0.99; Supplemental Figure 7Q6). However, there
550 was no main effect of SQ-LNS on plasma zinc concentrations, and in both aforementioned cases
551 of effect modification, the confidence intervals around the estimates in both sub-groups included
552 one; therefore, it is likely that there was no true effect on plasma zinc concentration in either sub-
553 group. No other maternal, child or household characteristics significantly modified the effect of
554 SQ-LNS on plasma zinc concentrations.

555 Maternal characteristics did not modify the effect of SQ-LNS on vitamin A status. There
556 was a greater effect of SQ-LNS on RBP concentrations among children with (vs. without)

557 inflammation at endline (GMR: 1.10 vs. 1.04; Supplemental Figure 6W9). There was also a
558 greater effect of SQ-LNS on the prevalence of marginal vitamin A status (RBP < 1.05 $\mu\text{mol/L}$)
559 among children in households with higher (vs. lower) SES (PR: 0.70 vs. 0.87; Supplemental
560 Figure 7Z1). In addition, we observed a greater effect of SQ-LNS on retinol concentrations
561 among children who were acutely malnourished (vs. non-malnourished) at baseline (GMR: 1.14
562 vs. 1.02; Supplemental Figure 6R6) and among children in mildly insecure or food secure (vs.
563 moderately to severely food insecure) households (GMR: 1.06 vs. 0.99; Supplemental Figure
564 7R2), although there was no main effect of SQ-LNS on plasma retinol concentrations.

565

566 Overview of individual-level effect modification

567 Table 4 and **Supplemental Table 8** show that some characteristics (e.g., birth order,
568 household water quality and sanitation, season and child inflammation) modified the effect of
569 SQ-LNS on a number of hematological and iron status biomarkers while others (e.g., maternal
570 education, child sex, child anemia at baseline, high-dose vitamin A supplementation, and
571 household food security) exhibited effect modification for only a few outcomes.

572 The results of the simulations to identify cutoff effects are indicated in Table 4 and
573 Supplemental Table 8. For example, among children who received SQ-LNS vs. control, the
574 prevalence of anemia was reduced by 18% among females and by 13% among males. However,
575 there was no significant effect modification for the continuous outcome (i.e., hemoglobin
576 concentration). Mean hemoglobin concentrations in the control group at endline were greater
577 among females than males (107 g/L vs. 105 g/L) and effect modification by sex became non-
578 significant for anemia prevalence in the simulation models; therefore, the cut-off effect is the
579 most likely explanation for these findings. The cut-off effect appeared to explain effect
580 modification by maternal BMI, with regard to the prevalence difference for IDA, and by

581 maternal education with regard to the prevalence difference for elevated ZPP. For the prevalence
582 of elevated sTfR (ratio and difference), the cutoff effect appeared to explain effect modification
583 by SES. The cutoff effect also appeared to contribute, at least partially, to the apparent effect
584 modification by sanitation for relative anemia prevalence (but not the prevalence difference for
585 anemia, nor the prevalence ratio or prevalence difference for moderate-to-severe anemia).

586 For maternal age, however, there was significant effect modification for hemoglobin
587 concentrations and both the prevalence ratio and prevalence difference for anemia, so this was
588 not due to the cutoff effect. In addition, the cutoff effect did not explain effect modification for
589 anemia by maternal BMI, birth order, inflammation or water quality, for iron deficiency by
590 season of outcome assessment, or for IDA and vitamin A deficiency by SES.

591

592 **Discussion**

593 This individual participant data analysis included 13 RCTs in nine different countries with a
594 total sample size of ~15,000 children. SQ-LNS substantially reduced the prevalence of anemia,
595 moderate-to-severe anemia, iron deficiency, and IDA among infants and young children who
596 received SQ-LNS for 3-18 months, relative to control children. The beneficial effects of SQ-LNS
597 on hemoglobin appeared to be greater among studies that were conducted in countries with a
598 high burden of anemia (>60%); greater beneficial effects of SQ-LNS on anemia and iron status
599 were observed among studies that provided SQ-LNS with a higher dose of iron and for a longer
600 duration. Several of the individual-level characteristics also appeared to modify the effects of
601 SQ-LNS on anemia and iron status. However, even when the magnitude of effect differed
602 between sub-groups, the magnitude of the modifying effects was generally small and we
603 observed positive effects of SQ-LNS within all sub-groups, indicating the potential of SQ-LNS

604 to provide benefits across a range of individual, population and study design characteristics. This
605 was also the case for the growth (19) and development (20) domains of this meta-analysis.

606

607 *Main effects of SQ-LNS on anemia and micronutrient status*

608 Children who received SQ-LNS had significantly higher hemoglobin concentrations
609 (2.77 g/L) relative to the control, and SQ-LNS reduced the prevalence of anemia and moderate to
610 severe anemia by 16% (10 percentage points) and 28% (7 percentage points), respectively.

611 Although these effects are smaller than what was reported in the 2019 Cochrane systematic
612 review and meta-analysis of LNS (SQ- or MQ-LNS) for hemoglobin (MD: 5.74 (2.27, 9.30) g/L)
613 and anemia (RR: 0.79 (0.69, 0.90)) (7), our meta-analysis includes a larger number of trials and
614 individual participants (N = 13 trials and 15,562 participants) as compared to the Das *et al.* meta-
615 analysis (N = 4-5 trials and 2,332-4,518 participants), which increases the precision of the effect
616 estimates. Furthermore, we report estimates for iron deficiency and IDA, which were not
617 included in the previous meta-analysis of SQ- and MQ-LNS. SQ-LNS reduced the prevalence of
618 iron deficiency (plasma ferritin < 12 µg/L) by 56% (22 percentage points) and the prevalence of
619 IDA by 64% (14 percentage points). At endline, the prevalence of IDA across all studies among
620 children in the control groups was 23.5%, compared with 7.9% among children who received
621 SQ-LNS. These large relative and absolute reductions in the prevalence of iron deficiency and
622 IDA due to SQ-LNS are important given that iron deficiency is the most common documented
623 micronutrient deficiency globally (4) and IDA is associated with compromised mental, motor,
624 socio-emotional and neural development (51).

625 The findings of the present SQ-LNS meta-analysis are similar to those reported in a
626 recent Cochrane systematic review and meta-analysis of the effect of multiple micronutrient
627 powders (MNP) on hemoglobin (MD: 2.74 (1.95, 3.53) g/L) and anemia (RR: 0.82 (0.76, 0.90))

628 (N = 16-20 trials and 9,927-10,509 participants) (52). Suchdev *et al.* also reported a 53%
629 reduction in the prevalence of iron deficiency (as defined by trialists) by MNP (N = 7 trials and
630 1,634 participants); the effect of MNP on the prevalence of IDA was not reported. Another meta-
631 analysis of MNP efficacy trials by Tam *et al.* reported relative reductions in the prevalence of
632 iron deficiency and IDA of 50% and 55%, respectively (8). Of note, in most of the MNP trials,
633 the dose of elemental iron was 10-12.5 mg/d (primarily as ferrous fumarate), whereas the SQ-
634 LNS trials in our analyses provided only 6-9 mg/d (primarily as ferrous sulfate).

635 In the present analyses, there was considerable heterogeneity in the effect of SQ-LNS on
636 anemia (reductions ranging from 3 to 29 percentage points), iron deficiency (reductions ranging
637 from 14 to 35 percentage points), and IDA (reductions ranging from 8 to 29 percentage points).
638 This heterogeneity may be due to differences in population characteristics (e.g., baseline
639 prevalence of anemia, iron deficiency and IDA, proportion of anemia attributable to nutritional
640 deficiencies vs. underlying burdens of infection and other causes) and study-design
641 characteristics. The more modest relative reduction in the prevalence of anemia than in IDA may
642 reflect the influence of non-nutritional causes of anemia in these populations (e.g., genetic
643 hemoglobin disorders and infection and inflammation including malaria, intestinal parasites and
644 schistosomiasis). In addition, although SQ-LNS substantially reduced the prevalence of IDA, it
645 did not completely eliminate IDA, possibly reflecting factors such as poor iron absorption (due
646 to anti-nutritional compounds, gastric pH or intestinal or systemic inflammation) (1) or a
647 hemoglobin cutoff for anemia that is set inappropriately high for infants and young children,
648 especially in African populations (53-55). However, it is noteworthy that the endline prevalence
649 of iron deficiency among children who received SQ-LNS was approximately 16% (vs. 40%

650 among children in the control groups), which is comparable to the prevalence of iron deficiency
651 among children 12-36 months of age in the United States of America (13.5%) (56).

652 We observed significant increases in RBP concentrations among children who received
653 SQ-LNS, although the relative increase was small (7%). The difference in plasma retinol was in
654 the same direction, but not statistically significant. Our ability to draw conclusions was limited
655 due to small sample sizes ($n = 663-1236$). However, in populations with adequate vitamin A
656 stores, serum retinol may not respond to an intervention due to homeostatic regulation (57). At
657 endline, the prevalence of vitamin A deficiency (retinol or $RBP < 0.70 \mu\text{mol/L}$) in the control
658 groups was low, ranging from 1.1 to 16.2%. In the majority of studies in this analysis that
659 assessed vitamin A status (7 of 9), more than half of study participants had received high-dose
660 vitamin A supplementation (100,000 – 200,000 IU) within the 6 months prior to outcome
661 assessment. Therefore, in some study contexts, the daily low-dose of vitamin A provided in SQ-
662 LNS may not have provided an additive benefit. However, SQ-LNS did reduce the prevalence of
663 vitamin A deficiency ($RBP < 0.70 \mu\text{mol/L}$) by 56% (corresponding to a modest 3 percentage
664 point reduction, due to the low overall prevalence of deficiency) indicating the potential of this
665 intervention to improve the status of those at-risk. There was no overall effect of the intervention
666 on plasma zinc concentrations, consistent with results from zinc-fortified food and MNP trials
667 (52, 58), potentially due to the low bioavailability of zinc in SQ-LNS when provided as part of a
668 phytate-rich food matrix (59), or differences in post-absorptive metabolism between zinc
669 supplements and zinc-fortified foods (60).

670

671 *Effect modification*

672 For both study- and individual-level effect modifiers, it is important to distinguish
673 between the potential to *benefit* and the potential to *respond* (18). The potential to benefit is more
674 likely when a population or an individual child is more vulnerable, e.g. due to a high prevalence
675 of anemia or micronutrient deficiencies in the study population at baseline. However, in some
676 cases, children who are more vulnerable may actually be *less* likely to respond to a nutritional
677 intervention because of other constraints on nutritional status such as infection and inflammation
678 or inadequate care. Thus, we will attempt to frame the following discussion of effect modifiers in
679 this context.

680 *Effect modification by study-level characteristics*

681 Studies included in this analysis were conducted in a variety of geographic and
682 environmental contexts (e.g., different regions, burdens of anemia and infection including
683 malaria, community-level access to improved water, sanitation and hygiene, etc.) and used
684 varying intervention designs (e.g. durations of supplementation, iron dose, frequency of contact
685 between participants and study staff) and this enables us to examine whether these study context
686 and design features modify the effects of SQ-LNS. However, it is difficult to disentangle the
687 impact attributable to one effect modifier from the influence of other characteristics of the study
688 and thus these results should be interpreted with caution. For example, studies that provided a
689 higher iron dose were more likely to provide SQ-LNS supplements for a longer duration, be
690 conducted in South Asia, and have a higher average compliance with supplementation (>80 %),
691 thus making it difficult to disentangle the impact attributable to each specific study-level
692 characteristic. In addition, it is important to note that due to concerns about adverse effects of
693 iron supplementation in malaria endemic areas (61, 62), a number of the SQ-LNS studies in
694 these analyses were purposefully designed to provide a lower iron dose in countries with a high
695 burden of malaria (6).

696 The effect of SQ-LNS on hemoglobin concentrations was greater in studies with a higher
697 burden of anemia (>60%), suggesting a greater potential to benefit from SQ-LNS in such
698 populations. Similarly, the effect of MNP on hemoglobin concentrations has been shown to be
699 greater in populations that were anemic at baseline vs. populations with mixed/unknown baseline
700 anemia status (MD: 4.53 g/L vs. 3.05 g/L) (52). However, even in populations with a lower
701 burden of anemia, both SQ-LNS and MNP significantly increased hemoglobin concentrations
702 and reduced the prevalence of anemia. In the present analyses, increases in hemoglobin
703 concentrations due to SQ-LNS were not significantly different between populations with and
704 without a high burden of malaria (4.29 g/L vs. 2.59 g/L) or inflammation (3.84 g/L vs. 3.21 g/L).
705 Thus, these results, coupled with the observation that statistically significant effects of SQ-LNS
706 were found in both subgroups, do not support the hypothesis that populations with a high burden
707 of malaria and inflammation have less of a potential to respond to iron interventions due to
708 increased hepcidin concentrations and down-regulation of iron absorption (63, 64).

709 Effect modification by study-level water quality and sanitation did not reach statistical
710 significance for the majority of hematological and iron status outcomes, with the exception of a
711 greater percentage point reduction in iron deficiency due to SQ-LNS in study sites with a lower
712 proportion of households with access to improved water quality and sanitation. This is likely due
713 to a higher prevalence of iron deficiency among children in the study sites with less access to
714 improved water quality and sanitation; among control group children, prevalence of iron
715 deficiency was 57% in those study sites, compared to 28% in sites with greater access.

716 Greater reductions in the prevalence of anemia and iron deficiency were observed in
717 trials that provided SQ-LNS for longer than 12 months, compared to a shorter duration (6-12
718 months). In addition, studies that reported higher average compliance (>80 %) showed greater

719 increases in hemoglobin concentrations and reductions in the prevalence of anemia, but we did
720 not observe significant effect modification by frequency of contact with programmatic or study
721 staff. Finally, we observed greater effects of SQ-LNS on the prevalence of anemia and increase
722 in ferritin concentrations among studies that provided 9 mg/d vs. < 9 mg/d iron. Although it may
723 be difficult to disentangle the impact attributable to each of these aforementioned study-level
724 characteristics, they all suggest a greater effect among studies in which children received a
725 higher total iron dose, either through a longer duration of supplementation, by higher
726 compliance, or a higher daily iron dose. Consistent with this, meta-analyses of the effectiveness
727 of MNP and iron supplements in infants and young children have also shown higher iron doses
728 to have a greater impact on iron and hematological status (8, 52).

729

730 *Effect modification by individual-level characteristics*

731 The effects of SQ-LNS on hemoglobin concentrations and the prevalence of anemia were
732 greater among children of older mothers compared to those of younger mothers (relative
733 reductions in anemia of 17% vs. 13%, respectively). Similarly, SQ-LNS had a larger effect on
734 both hemoglobin and ferritin concentrations among later-born, as compared with first-born
735 children, and reduced the prevalence of anemia in these sub-groups by 12 vs. 7 percentage
736 points, respectively. SQ-LNS also had a larger effect on stunting, underweight and MUAC
737 among later-born vs. first-born children (19). These results likely indicate a greater potential to
738 benefit among later-born children. For example, hemoglobin concentrations among control group
739 children in this IPD analysis were lower among later-born than first-born children (105.5 g/L vs.
740 108.4 g/L). Later-born children, who have one or more older siblings, may compete more for
741 caregiving and family resources than first-born children, making them more vulnerable to
742 anemia and iron deficiency and therefore more likely to benefit from nutritional supplementation

743 targeted specifically to young children. In addition, later-born children, who are more likely to be
744 born to older mothers, may be more vulnerable to micronutrient deficiencies due to poor
745 maternal physiological status owing to high fertility rates and short inter-pregnancy intervals (65,
746 66).

747 The effects of SQ-LNS on biomarkers of hematological and iron status (i.e., ferritin,
748 sTfR, ZPP) did not differ by child sex, with the exception of greater reductions in ZPP
749 concentrations due to SQ-LNS among males vs. females (24% vs. 18%). The former may have
750 had a greater potential to benefit, given that median ZPP concentrations were higher among
751 control group males than females in this analysis (62.0 $\mu\text{mol/mol}$ heme vs. 53.1 $\mu\text{mol/mol}$
752 heme), and males tend to be more vulnerable to iron deficiency in infancy (67). However, both
753 sexes responded positively to the intervention, with a 10 percentage point reduction in the
754 prevalence of anemia and a 20-23 percentage point reduction in the prevalence of iron
755 deficiency. Children who were anemic at baseline had greater increases in hemoglobin
756 concentrations due to SQ-LNS than children who were not anemic at baseline, indicating a
757 greater potential to benefit. A recent MNP trial also showed greater increases in hemoglobin
758 concentrations due to MNP among children who were anemic vs. non-anemic at baseline (68). In
759 addition, these results are consistent with our study-level effect modification results, which
760 indicated that increases in hemoglobin due to SQ-LNS were greater in populations with a high
761 vs. moderate burden of anemia. Increases in ferritin concentrations due to SQ-LNS were larger
762 among children who were acutely malnourished at baseline, compared to those who were not.
763 Among children in the control groups, median ferritin concentrations were lower among children
764 with vs. without acute malnutrition (15.5 $\mu\text{g/L}$ vs. 19.5 $\mu\text{g/L}$), also suggestive of a greater
765 potential to benefit.

766 Although differences in the ability of populations to benefit or respond to SQ-LNS by the
767 study-level burden of malaria or inflammation appeared to be explained by the cut-off effect, we
768 did observe some differences at the individual level. SQ-LNS reduced the prevalence of anemia
769 by 34% (a 12 percentage point difference) among children without concurrent inflammation vs.
770 15% (a 5 percentage point difference) among children with elevated CRP and/or AGP
771 concentrations, indicating a greater potential to respond among those without inflammation. As
772 inflammation is itself a cause of anemia (i.e., anemia of chronic disease) and can inhibit
773 absorption of iron (63), it is likely that a higher proportion of anemia in the subgroup of non-
774 inflamed children was amenable to nutritional supplementation. Among children with
775 inflammation, non-nutritional causes of anemia may have been more prevalent (e.g., anemia
776 attributable to acute or chronic infection and inflammation) (29, 69). In the present analyses, the
777 proportion of anemia not due to iron deficiency was greater (54% vs. 35%) among children with
778 inflammation vs. those without. In addition, it is possible that children without inflammation had
779 a greater fractional absorption of iron relative to those with inflammation (70). Hepcidin, an
780 important regulator of systemic iron balance, is elevated by inflammation thereby inhibiting iron
781 absorption (63). While a few trials measured hepcidin, we had insufficient data to examine it in
782 this analysis. However, greater increases in ferritin concentrations due to SQ-LNS were observed
783 among children without inflammation (65% vs. 48%), although there were no differences in the
784 effect of SQ-LNS on iron deficiency by inflammation status.

785 Greater effects of SQ-LNS on reductions in the prevalence of anemia, and reductions in
786 sTfR concentrations, were seen among children in households with improved (vs. unimproved)
787 water quality. Poor quality water or sanitation may increase the risk of anemia due to infection
788 with soil transmitted helminths or environmental enteric dysfunction, which may increase

789 inflammation or reduce nutrient absorption. Among children in the control group, the prevalence
790 of anemia was higher among children without (vs. with) access to improved water quality (69%
791 vs. 56%). Thus, this effect modification might be seen as consistent with the inflammation effect
792 modification results described above. Children with less exposure to gastrointestinal pathogens
793 through contaminated water supplies may have less inflammation and thus may be more able to
794 respond to the SQ-LNS intervention. However, these findings are in contrast with the observed
795 greater effects of SQ-LNS on anemia and moderate-to-severe anemia among children in
796 households with unimproved (vs. improved) sanitation. This may indicate a greater potential to
797 benefit, given that the prevalences of anemia and moderate-to-severe anemia were higher among
798 control group children in households with unimproved sanitation (by 7 and 10 percentage points,
799 respectively). The contradictory effect modification results for water quality and sanitation are
800 difficult to explain. It is notable, though, that water quality and sanitation did not modify the
801 effect of SQ-LNS on hemoglobin concentrations, and there was evidence of beneficial effects of
802 SQ-LNS in all subgroups of children.

803 Greater effects of SQ-LNS on ferritin concentrations and the prevalence of iron
804 deficiency were seen among children for whom biomarkers were assessed in the rainy season.
805 Among children in the control groups in this analysis, median ferritin concentrations were lower
806 (13.9 $\mu\text{g/L}$ vs. 16.1 $\mu\text{g/L}$), and the prevalence of iron deficiency higher (by 6 percentage points)
807 when outcome assessments occurred during the rainy (vs. dry) season. Thus, it is possible that
808 this represents a greater potential to benefit, whereby the supplemental iron provided by SQ-LNS
809 compensates for seasonal differences in dietary intake and/or constraints on iron absorption (e.g.,
810 infection and inflammation). However, iron status at a given point in time reflects the cumulative
811 effect of intake, absorption and utilization over many months, so it is unclear whether effect

812 modification by season is due to short-term, acute phenomena or longer-term exposure to
813 adverse conditions that is correlated with season at outcome assessment. Other household-level
814 characteristics, including SES and food security, did not generally modify the effect of SQ-LNS
815 on anemia or iron biomarker outcomes.

816 With regard to individual-level effect modification of outcomes related to zinc and
817 vitamin A status, observed differences between the stratum-specific point estimates were
818 generally small even when there were statistically significant p-values. In the latter situation,
819 results were generally consistent with effect modification for hematological and iron status
820 biomarkers, whereby children of older mothers, children who were acutely malnourished at
821 baseline, children in households of higher SES and with greater food security, and children
822 assessed during the rainy season had greater increases in biomarker concentrations or reductions
823 in the prevalence of deficiency vs. those in the respective comparison sub-groups.

824

825 *Strengths and limitations*

826 Strengths of the present analyses include the large sample size, the substantial number of
827 high-quality RCTs available, and the availability of individual participant data for all but one of
828 the eligible trials. In addition, we were able to report the effects of SQ-LNS on multiple
829 indicators of micronutrient status that had not been included in prior meta-analyses. The majority
830 of trials used the same analytical laboratory and platform for several biomarkers (ferritin, sTfR,
831 RBP; Vit-Min Lab) or standardized analytical methods (ZPP), lending strength to the findings.
832 The trial sites were diverse in terms of study context (e.g., burdens of anemia, malaria and
833 inflammation) and design (e.g., iron dose and duration of supplementation), which provided
834 heterogeneity for exploration of study-level effect modifiers. The findings were generally

835 consistent across sensitivity analyses, as well as between fixed- and random-effects models,
836 adding strength to the conclusions.

837 Several limitations must be considered. Bangladesh was the only country represented in
838 these analyses outside of sub-Saharan Africa. Although hemoglobin data were available for all
839 thirteen trials, fewer studies assessed biomarkers of iron, zinc and vitamin A status (3-7 studies)
840 and sample sizes for each of those biomarkers were smaller (1,133 – 3,078 vs. 15,398 for
841 hemoglobin). In addition, data were not yet available from a sufficient number of studies to be
842 able to investigate the effects of SQ-LNS on additional biomarkers, including plasma hepcidin,
843 folate, and vitamin B12 concentrations. Furthermore, not all trials assessed both CRP and AGP
844 in all children at endline, potentially limiting the accuracy of adjustments for inflammation
845 and/or reducing the available sample size. It should also be noted that a single assessment of
846 inflammation may not adequately characterize the inflammation status of individual children
847 over time, and the effects that average inflammation status over the entire period of
848 supplementation may have on micronutrient status.

849 Due to limitations in the data (e.g., number of studies that assessed biomarker outcomes
850 or effect modifiers of interest, or a low prevalence of the binary outcome or proportion of
851 children within one of the effect modifier subgroups), we were unable to generate effect
852 estimates of SQ-LNS on all biomarkers by all potential effect modifiers for all trials. Overall,
853 statistical power for study-level effect modification was constrained by the limited number of
854 trials, so there may be meaningful differences in effect estimates between categories of trials
855 even if the p-diff for interaction was not significant. On the other hand, the individual-level
856 effect modification analyses involved multiple effect modifiers and numerous outcomes, so
857 several of the significant p-for-interaction values are likely due to chance. As stated in the

858 Methods section, we did not adjust for multiple hypothesis testing because the effect
859 modification analyses are inherently exploratory. Finally, effect modification results should be
860 interpreted with caution, as potential effect modifiers may be inter-related or confounded by
861 unmeasured variables. This is particularly important for study-level characteristics because, as
862 previously noted, it was not possible to completely disentangle the impact attributable to a
863 specific effect modifier from the impact attributable to other characteristics of the study (e.g.,
864 study design, context, implementation, etc.).

865

866 *Programmatic Implications*

867 The present findings suggest that policy-makers and program planners should consider
868 SQ-LNS in the mix of interventions to prevent anemia and iron and vitamin A deficiencies. The
869 overall effects of SQ-LNS on iron deficiency (56% reduction) and IDA (64% reduction) were
870 substantial and may improve child neurological development and immune function (71).
871 Although the overall effects on anemia and moderate-to-severe anemia were more modest (16%
872 and 28% reductions, respectively), this likely reflects the presence of anemias in these
873 populations that are not nutrition responsive (e.g., genetic hemoglobin disorders and infection
874 and inflammation). Alternative interventions, including micronutrient supplementation, MNP
875 and food fortification are also effective in reducing anemia and the prevalence of iron deficiency
876 (8, 52); however, SQ-LNS provides the added benefits of reducing mortality (72), stunting and
877 wasting (19) and improving developmental outcomes (20).

878 In terms of program design, the effect modification results herein suggest that a greater
879 impact of SQ-LNS on hematological and iron status outcomes may be obtained by providing
880 formulations with the higher dose of iron (9 mg/d) and/or providing SQ-LNS for the entire
881 window from 6-24 months. The iron dose of fortified products has been of concern because of

882 evidence that iron-containing supplements and MNP may increase susceptibility to malaria in
883 endemic regions, as well as respiratory and gastrointestinal infections (61, 73-75), although two
884 recent systematic reviews and meta-analyses did not indicate any increase in the risk of diarrhea
885 or malaria from these interventions (52, 76). The present analysis did not examine potential
886 adverse impacts (e.g., morbidity or mortality) of SQ-LNS by iron dose, malaria burden or other
887 potential effect modifiers. However, most published trials have not reported differences in
888 diarrheal or malarial morbidity between SQ-LNS and control groups (40, 42-44, 47, 48, 77-79),
889 and some reported beneficial effects of SQ-LNS on diarrheal prevalence (37) and duration of
890 pneumonia, diarrhea and dysentery (35). In addition, a recent meta-analysis reported an overall
891 27% reduction in the risk of mortality among children who received SQ-LNS vs. control (72).
892 The majority of studies providing the higher iron dose were in lower malaria burden sites (36,
893 37, 42), and as such, we cannot recommend universal use of higher iron dose SQ-LNS
894 supplements at this time. In areas with a low prevalence of malaria and inflammation, or in
895 malaria endemic areas with a well-integrated control program with appropriate surveillance and
896 the prevention and management of malaria, providing the higher iron dose (9 mg/d) in SQ-LNS
897 may be appropriate and have a greater impact on iron status and hematological parameters.
898 Provision of SQ-LNS containing 9 mg/d iron for 18 months would cumulatively provide
899 approximately 4,925 mg of iron, compared with the 2,200 mg of iron provided by 12 months of
900 SQ-LNS containing 6 mg/d iron, but would increase programmatic costs.

901 The effect modification results for biochemical outcomes generally did not provide a
902 strong rationale for *targeting* SQ-LNS only to the most vulnerable children or populations. Even
903 in situations that were indicative of a greater potential to benefit among one sub-group compared
904 to another (e.g., greater increases in hemoglobin concentrations among later-born vs. first-born

905 children and among anemic vs. non-anemic children, greater increases in ferritin concentrations
906 among acutely malnourished vs. non-malnourished children), both sub-groups responded
907 positively and appeared to benefit from the intervention. However, some of the results suggested
908 that a greater impact of SQ-LNS may be obtained by *combining* supplementation with
909 interventions that address factors related to the potential to respond. Integrating the provision of
910 SQ-LNS with interventions to address the prevention and control of infection and inflammation
911 (e.g., household and/or community level improvements in water, sanitation and hygiene, use of
912 insecticide treated bed nets, and surveillance and treatment of diarrhea and malaria) may increase
913 nutrient (iron) absorption, and thus increase the efficacy of the supplement.

914 There is now substantial evidence demonstrating the efficacy of SQ-LNS for prevention
915 of anemia and iron deficiency. However, further research is needed to investigate the efficacy of
916 SQ-LNS for prevention of other vitamin and mineral deficiencies. In the present analysis, there
917 was insufficient evidence to assess the effect of SQ-LNS on folate and vitamin B12 status, and
918 no trials assessed status regarding other B-vitamins, vitamin C, vitamin D and vitamin E, or
919 minerals other than iron and zinc. Additional research is also needed on the optimal iron dose in
920 SQ-LNS and the duration of supplementation, with regard to not only iron status and anemia but
921 also morbidity, the costs and benefits of shorter vs. longer supplementation, and the potential to
922 align the intervention with periods of increased vulnerability. Finally, further research would be
923 useful to determine the optimal doses and formulations of micronutrients to include in SQ-LNS,
924 and to investigate the effect of additional compounds, such as phytase or galacto-
925 oligosaccharides, that may improve mineral bioavailability.

926 **Acknowledgments**

927 We thank all of the co-investigators, collaborators, study teams, participants and local
928 communities involved in the trials included in these analyses. These trials benefitted from the
929 contributions of many partner organizations, including: icddr,b (JiVitA-4, Rang-Din Nutrition
930 Study and WASH Benefits trial in Bangladesh); the World Food Program (JiVitA-4 trial in
931 Bangladesh); the Health District of Dandé and the relevant local health-care authorities (iLiNS-
932 ZINC trial in Burkina Faso); AfricSanté and Helen Keller International (PROMIS trials in
933 Burkina Faso and Mali); Innovations for Poverty Action and the Kenya Medical Research
934 Institute (WASH-Benefits trial in Kenya); Unité Programme National de Nutrition
935 Communautaire, Government of Madagascar, Institute Pasteur, and World Bank Health and
936 Nutrition and Population Global Practice (MAHAY trial in Madagascar); the Ministry of Health
937 and Child Care in Harare, Chirumanzu and Shurugwi districts, and Midlands Province (SHINE
938 trial in Zimbabwe); the International Lipid-based Nutrient Supplements Project Steering
939 Committee (iLiNS Project trials); and Nutriset (for development of SQ-LNS). We thank Emily
940 Smith for advice on IPD analysis methods.

941
942
943 The authors' responsibilities were as follows—KRW: drafted the manuscript with input from
944 KGD, CDA, ELP, CPS and other coauthors; KRW, CDA, KGD, ELP and CPS: wrote the
945 statistical analysis plan; BFA, PA, EB, LH: reviewed, contributed to, and approved the statistical
946 analysis plan; KRW and CDA: compiled the data; CDA: conducted the data analysis; and all
947 authors: read, contributed to, and approved the final manuscript.

948

949 Supported by Bill & Melinda Gates Foundation grant OPP49817 (to KGD). BA received travel
950 support (airfare and hotel) covered by the Bill & Melinda Gates Foundation to attend meetings in
951 Seattle during the period of this IPD analysis project; PC was an employee of the Bill & Melinda
952 Gates Foundation when this project was conceived until December 2019. All other authors report
953 no conflicts of interest.

REFERENCES

1. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, Ezzati M, Grantham-McGregor S, Katz J, Martorell R, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet* 2013;382:427-51.
2. Muthayya S, Rah JH, Sugimoto JD, Roos FF, Kraemer K, Black RE. The global hidden hunger indices and maps: an advocacy tool for action. *PLoS One* 2013;8:e67860.
3. Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, Regan M, Weatherall D, Chou DP, Eisele TP, et al. A systematic analysis of global anemia burden from 1990 to 2010. *Blood* 2014;123:615-24.
4. Bailey RL, West KP, Jr., Black RE. The epidemiology of global micronutrient deficiencies. *Ann Nutr Metab* 2015;66 Suppl 2:22-33.
5. United Nations Children's Fund (UNICEF). *Improving Child Nutrition: The Achievable Imperative for Global Progress*. New York, UNICEF, 2013. Available at: https://www.unicef.org/publications/index_68661.html. Accessed on: 25 September 2020.
6. Arimond M, Zeilani M, Jungjohann S, Brown KH, Ashorn P, Allen LH, Dewey KG. Considerations in developing lipid-based nutrient supplements for prevention of undernutrition: experience from the International Lipid-Based Nutrient Supplements (iLiNS) Project. *Matern Child Nutr* 2015;11 Suppl 4:31-61.
7. Das JK, Salam RA, Hadi YB, Sadiq Sheikh S, Bhutta AZ, Weise Prinzo Z, Bhutta ZA. Preventive lipid-based nutrient supplements given with complementary foods to infants and young children 6 to 23 months of age for health, nutrition, and developmental outcomes. *Cochrane Database Syst Rev* 2019;5:CD012611.
8. Tam E, Keats EC, Rind F, Das JK, Bhutta AZA. Micronutrient supplementation and fortification interventions on health and development outcomes among children under-five in low- and middle-income countries: a systematic review and meta-analysis. *Nutrients* 2020;12:289.
9. Adu-Afarwah S, Lartey A, Brown KH, Zlotkin S, Briend A, Dewey KG. Home fortification of complementary foods with micronutrient supplements is well accepted and has positive effects on infant iron status in Ghana. *Am J Clin Nutr* 2008;87:929-38.
10. Matias SL, Mridha MK, Young RT, Khan MSA, Siddiqui Z, Ullah MB, Vosti SA, Dewey KG. Prenatal and postnatal supplementation with lipid-based nutrient supplements reduces anemia and iron deficiency in 18-month-old Bangladeshi children: a cluster-randomized effectiveness trial. *J Nutr* 2018;148:1167-76.
11. Abbeddou S, Jimenez E, Some J, Ouedraogo J, Brown KH, Hess S. Small-quantity lipid-based nutrient supplements containing different amounts of zinc along with diarrhea and malaria treatment increase iron and vitamin A status and reduce anemia prevalence, but do not affect zinc status in young Burkinabe children: a cluster-randomized trial. *BMC Pediatrics* 2017;17.
12. Stewart CP, Dewey KG, Lin A, Pickering AJ, Byrd KA, Jannat K, Ali S, Rao G, Dentz HN, Kiprotich M, et al. Effects of lipid-based nutrient supplements and infant and young child feeding counseling with or without improved water, sanitation, and hygiene (WASH) on anemia and micronutrient status: results from 2 cluster-randomized trials in Kenya and Bangladesh. *Am J Clin Nutr* 2019;109:148-64.

13. Stewart CP, Fernald LCH, Weber AM, Arnold C, Galasso E. Lipid-based nutrient supplementation reduces child anemia and increases micronutrient status in Madagascar: a multiarm cluster-randomized controlled trial. *J Nutr* 2020;150:958-66.
14. Smuts CM, Matsungo TM, Malan L, Kruger HS, Rothman M, Kvalsvig JD, Covic N, Joosten K, Osendarp SJM, Bruins MJ, et al. Effect of small-quantity lipid-based nutrient supplements on growth, psychomotor development, iron status, and morbidity among 6- to 12-mo-old infants in South Africa: a randomized controlled trial. *Am J Clin Nutr* 2019;109:55-68.
15. Campbell RK, Shaikh S, Schulze K, Arguello M, Ali H, Wu L, West KP, Jr., Christian P. Micronutrient and inflammation status following one year of complementary food supplementation in 18-month-old rural Bangladeshi children: a randomized controlled trial. *Nutrients* 2020;12.
16. Adu-Afarwuah S, Young RT, Lartey A, Okronipa H, Ashorn P, Ashorn U, Oaks BM, Arimond M, Dewey KG. Maternal and infant supplementation with small-quantity lipid-based nutrient supplements increases infants' iron status at 18 months of age in a semiurban setting in Ghana: a secondary outcome analysis of the iLiNS-DYAD randomized controlled trial. *J Nutr* 2019;149:149-58.
17. Dewey KG, Mridha MK, Matias SL, Cummins JR, Arnold CD, Young RT, Maalouf-Manasseh Z, Vosti SA. Effectiveness of home fortification with lipid-based nutrient supplements (LNS) or micronutrient powder on child growth, development, micronutrient status, and health expenditures in Bangladesh. . Washington, DC: FHI 360/Food and Nutrition Technical Assistance III Project (FANTA). 2017.
18. Dewey KG. Reducing stunting by improving maternal, infant and young child nutrition in regions such as South Asia: evidence, challenges and opportunities. *Matern Child Nutr* 2016;12 Suppl 1:27-38.
19. Dewey KG, Wessells KR, Arnold CD, Prado EL, Abbeddou S, Adu-Afarwuah S, Ali H, Arnold BF, Ashorn P, Ashorn U, et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child growth: an individual participant data meta-analysis of randomized controlled trials. *Amer J Clin Nutr*, in this supplement.
20. Prado EL, Arnold CD, Wessells KR, Stewart CP, Abbeddou S, Adu-Afarwuah S, Arnold BF, Ashorn U, Ashorn P, Becquey E, et al. Small-quantity lipid-based nutrient supplements for children age 6-24 months: a systematic review and individual participant data meta-analysis of effects on developmental outcomes and effect modifiers. *Amer J Clin Nutr*, in this supplement.
21. Wessells K, Dewey K, Stewart C, Arnold C, Prado E. Modifiers of the effect of LNS provided to infants and children 6 to 24 months of age on anemia and MN status outcomes: a systematic review and meta-analysis of individual participant data from randomized controlled trials in low-income and middle-income countries. PROSPERO 2020 CRD42020156663 Available from: https://www.crd.york.ac.uk/prospERO/display_record.php?ID=CRD42020156663.
22. Wessells KR, Stewart C, Arnold CD, Dewey K, Prado E. Modifiers of the effect of LNS provided to infants and children 6 to 24 months of age on growth, anemia, micronutrient status and development outcomes. Open Science Framework. Available from: <https://osf.io/ymsfu>.

23. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF, Group P-ID. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. *JAMA* 2015;313:1657-65.
24. World Bank Historical Classification by Income Group. Available at: <http://databank.worldbank.org/data/download/site-content/OGHIST.xls> Accessed on: 22 August 2019.
25. Johnston BC, Guyatt GH. Best (but oft-forgotten) practices: intention-to-treat, treatment adherence, and missing participant outcome data in the nutrition literature. *Am J Clin Nutr* 2016;104:1197-201.
26. Higgins J, Green S. *Cochrane Handbook for Systematic Reviews for Interventions*, Version 5.1.0. The Cochrane Collaboration 2011. Available from www.handbook.cochrane.org.
27. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011;64:401-6.
28. World Health Organization. Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. Geneva, World Health Organization, 2001.
29. Namaste SM, Aaron GJ, Varadhan R, Peerson JM, Suchdev PS, Brinda Working Group. Methodologic approach for the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. *Am J Clin Nutr* 2017;106:333S-47S.
30. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. *Stat Med* 2017;36:855-75.
31. Huber PJ. The behavior of maximum likelihood estimates under non-standard conditions. *Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability*; University of California Press; Berkeley, CA. 1967. pp. 221–233.
32. Paule RC, Mandel J. Consensus values, regressions, and weighting factors. *J Res Natl Inst Stand Technol* 1989;94:197-203.
33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.
34. Streiner DL. Best (but oft-forgotten) practices: the multiple problems of multiplicity—whether and how to correct for many statistical tests. *Am J Clin Nutr* 2015;102:721-8.
35. Christian P, Shaikh S, Shamim AA, Mehra S, Wu L, Mitra M, Ali H, Merrill RD, Choudhury N, Parveen M, et al. Effect of fortified complementary food supplementation on child growth in rural Bangladesh: a cluster-randomized trial. *Int J Epidemiol* 2015;44:1862-76.
36. Dewey KG, Mridha MK, Matias SL, Arnold CD, Cummins JR, Khan MS, Maalouf-Manasseh Z, Siddiqui Z, Ullah MB, Vosti SA. Lipid-based nutrient supplementation in the first 1000 d improves child growth in Bangladesh: a cluster-randomized effectiveness trial. *Am J Clin Nutr* 2017;105:944-57.
37. Luby SP, Rahman M, Arnold BF, Unicomb L, Ashraf S, Winch PJ, Stewart CP, Begum F, Hussain F, Benjamin-Chung J, et al. Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Bangladesh: a cluster randomised controlled trial. *Lancet Glob Health* 2018;6:e302-e15.
38. Hess SY, Abbeddou S, Jimenez EY, Some JW, Vosti SA, Ouedraogo ZP, Guissou RM, Ouedraogo JB, Brown KH. Small-quantity lipid-based nutrient supplements, regardless

- of their zinc content, increase growth and reduce the prevalence of stunting and wasting in young Burkinabe children: a cluster-randomized trial. *PLoS One* 2015;10:e0122242.
39. Becquey E, Huybregts L, Zongrone A, Le Port A, Leroy JL, Rawat R, Toure M, Ruel MT. Impact on child acute malnutrition of integrating a preventive nutrition package into facility-based screening for acute malnutrition during well-baby consultation: a cluster-randomized controlled trial in Burkina Faso. *PLoS Med* 2019;16:e1002877.
 40. Adu-Afarwuah S, Lartey A, Brown KH, Zlotkin S, Briend A, Dewey KG. Randomized comparison of 3 types of micronutrient supplements for home fortification of complementary foods in Ghana: effects on growth and motor development. *Am J Clin Nutr* 2007;86:412-20.
 41. Adu-Afarwuah S, Lartey A, Okronipa H, Ashorn P, Peerson JM, Arimond M, Ashorn U, Zeilani M, Vosti S, Dewey KG. Small-quantity, lipid-based nutrient supplements provided to women during pregnancy and 6 mo postpartum and to their infants from 6 mo of age increase the mean attained length of 18-mo-old children in semi-urban Ghana: a randomized controlled trial. *Am J Clin Nutr* 2016;104:797-808.
 42. Null C, Stewart CP, Pickering AJ, Dentz HN, Arnold BF, Arnold CD, Benjamin-Chung J, Clasen T, Dewey KG, Fernald LCH, et al. Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Kenya: a cluster-randomised controlled trial. *Lancet Glob Health* 2018;6:e316-e29.
 43. Galasso E, Weber AM, Stewart CP, Ratsifandrihamanana L, Fernald LCH. Effects of nutritional supplementation and home visiting on growth and development in young children in Madagascar: a cluster-randomised controlled trial. *Lancet Glob Health* 2019;7:e1257-e68.
 44. Ashorn P, Alho L, Ashorn U, Cheung YB, Dewey KG, Gondwe A, Harjunmaa U, Lartey A, Phiri N, Phiri TE, et al. Supplementation of maternal diets during pregnancy and for 6 months postpartum and infant diets thereafter with small-quantity lipid-based nutrient supplements does not promote child growth by 18 months of age in rural Malawi: a randomized controlled trial. *J Nutr* 2015;145:1345-53.
 45. Maleta KM, Phuka J, Alho L, Cheung YB, Dewey KG, Ashorn U, Phiri N, Phiri TE, Vosti SA, Zeilani M, et al. Provision of 10-40 g/d lipid-based nutrient supplements from 6 to 18 months of age does not prevent linear growth faltering in Malawi. *J Nutr* 2015;145:1909-15.
 46. Huybregts L, Le Port A, Becquey E, Zongrone A, Barba FM, Rawat R, Leroy JL, Ruel MT. Impact on child acute malnutrition of integrating small-quantity lipid-based nutrient supplements into community-level screening for acute malnutrition: a cluster-randomized controlled trial in Mali. *PLoS Med* 2019;16:e1002892.
 47. Humphrey JH, Mbuya MNN, Ntozini R, Moulton LH, Stoltzfus RJ, Tavengwa NV, Mutasa K, Majo F, Mutasa B, Mangwadu G, et al. Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting and anaemia in rural Zimbabwe: a cluster-randomised trial. *Lancet Glob Health* 2019;7:e132-e47.
 48. Prendergast AJ, Chasekwa B, Evans C, Mutasa K, Mbuya MNN, Stoltzfus RJ, Smith LE, Majo FD, Tavengwa NV, Mutasa B, et al. Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on stunting and anaemia among HIV-exposed children in rural Zimbabwe: a cluster-randomised controlled trial. *Lancet Child Adolesc Health* 2019;3:77-90.

49. Iannotti LL, Dulience SJ, Green J, Joseph S, Francois J, Antenor ML, Lesorogol C, Mounce J, Nickerson NM. Linear growth increased in young children in an urban slum of Haiti: a randomized controlled trial of a lipid-based nutrient supplement. *Am J Clin Nutr* 2014;99:198-208.
50. World Malaria Report 2018. Geneva: World Health Organization; 2018. Available at: <https://www.who.int/malaria/publications/world-malaria-report-2018/report/en/> Accessed on: 26 August 2019.
51. Walker SP, Wachs TD, Gardner JM, Lozoff B, Wasserman GA, Pollitt E, Carter JA, International Child Development Steering G. Child development: risk factors for adverse outcomes in developing countries. *Lancet* 2007;369:145-57.
52. Suchdev PS, Jefferds MED, Ota E, da Silva Lopes K, De-Regil LM. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. *Cochrane Database Syst Rev* 2020;2:CD008959.
53. Domellof M, Dewey KG, Lonnerdal B, Cohen RJ, Hernell O. The diagnostic criteria for iron deficiency in infants should be reevaluated. *J Nutr* 2002;132:3680-6.
54. Nestel P and the INACG Steering Committee. Adjusting hemoglobin values in program surveys. Available from: http://pdf.usaid.gov/pdf_docs/PNACQ927.pdf. Accessed on: 2 December 2020.
55. Jorgensen JM, Crespo-Bellido M, Dewey KG. Variation in hemoglobin across the life cycle and between males and females. *Ann N Y Acad Sci* 2019;1450:105-25.
56. Gupta PM, Perrine CG, Mei Z, Scanlon KS. Iron, anemia, and iron deficiency anemia among young children in the United States. *Nutrients* 2016;8.
57. Tanumihardjo SA, Russell RM, Stephensen CB, Gannon BM, Craft NE, Haskell MJ, Lietz G, Schulze K, Raiten DJ. Biomarkers of Nutrition for Development (BOND)-Vitamin A Review. *J Nutr* 2016;146:1816S-48S.
58. Hess SY, Brown KH. Impact of zinc fortification on zinc nutrition. *Food Nutr Bull* 2009;30:S79-107.
59. Zyba SJ, Wegmuller R, Woodhouse LR, Ceesay K, Prentice AM, Brown KH, Wessells KR. Effect of exogenous phytase added to small-quantity lipid-based nutrient supplements (SQ-LNS) on the fractional and total absorption of zinc from a millet-based porridge consumed with SQ-LNS in young Gambian children: a randomized controlled trial. *Am J Clin Nutr* 2019;110:1465-75.
60. King JC, Brown KH, Gibson RS, Krebs NF, Lowe NM, Siekmann JH, Raiten DJ. Biomarkers of Nutrition for Development (BOND) - Zinc Review. *J Nutr* 2016;146:858S-85S.
61. Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, Dhingra U, Kabole I, Deb S, Othman MK, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. *Lancet* 2006;367:133-43.
62. Report of the World Health Organization Technical Consultation on Prevention and Control of Iron Deficiency in Infants and Young Children in Malaria-Endemic Areas, Lyon, France, 12-14 June 2006. *Food Nutr Bull* 2007;28:S489-631.
63. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. *Acta Haematol* 2009;122:78-86.

64. Muriuki JM, Atkinson SH. How eliminating malaria may also prevent iron deficiency in African children. *Pharmaceuticals (Basel)* 2018;11.
65. King JC. The risk of maternal nutritional depletion and poor outcomes increases in early or closely spaced pregnancies. *J Nutr* 2003;133:1732S-6S.
66. Winkvist A, Rasmussen KM, Habicht JP. A new definition of maternal depletion syndrome. *Am J Public Health* 1992;82:691-4.
67. Domellof M, Lonnerdal B, Dewey KG, Cohen RJ, Rivera LL, Hernell O. Sex differences in iron status during infancy. *Pediatrics* 2002;110:545-52.
68. Barffour MA, Hinnouho GM, Kounnavong S, Wessells KR, Ratsavong K, Bounheuang B, Chanhthavong B, Sithideth D, Sengnam K, Arnold CD, et al. Effects of daily zinc, daily multiple micronutrient powder, or therapeutic zinc supplementation for diarrhea prevention on physical growth, anemia, and micronutrient status in rural Laotian children: a randomized controlled trial. *J Pediatr* 2019;207:80-9.
69. Balarajan Y, Ramakrishnan U, Ozaltin E, Shankar AH, Subramanian SV. Anaemia in low-income and middle-income countries. *Lancet* 2011;378:2123-35.
70. Hurrell RF. Influence of inflammatory disorders and infection on iron absorption and efficacy of iron-fortified foods. *Nestle Nutr Inst Workshop Ser* 2012;70:107-16.
71. Armitage AE, Moretti D. The importance of iron status for young children in low- and middle-income countries: a narrative review. *Pharmaceuticals (Basel)* 2019;12.
72. Stewart CP, Wessells KR, Arnold CD, Huybregts L, Ashorn P, Becquey E, Humphrey JH, Dewey KG. Lipid-based nutrient supplements and all-cause mortality in children 6-24 months of age: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* 2020;111:207-18.
73. Soofi S, Cousens S, Iqbal SP, Akhund T, Khan J, Ahmed I, Zaidi AK, Bhutta ZA. Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: a cluster-randomised trial. *Lancet* 2013;382:29-40.
74. Veenemans J, Milligan P, Prentice AM, Schouten LR, Inja N, van der Heijden AC, de Boer LC, Jansen EJ, Koopmans AE, Enthoven WT, et al. Effect of supplementation with zinc and other micronutrients on malaria in Tanzanian children: a randomised trial. *PLoS Med* 2011;8:e1001125.
75. Paganini D, Uyoga MA, Zimmermann MB. Iron fortification of foods for infants and children in low-income countries: effects on the gut microbiome, gut inflammation, and diarrhea. *Nutrients* 2016;8.
76. Pasricha SR, Hayes E, Kalumba K, Biggs BA. Effect of daily iron supplementation on health in children aged 4-23 months: a systematic review and meta-analysis of randomised controlled trials. *Lancet Glob Health* 2013;1:e77-e86.
77. Ullah MB, Mridha MK, Arnold CD, Matias SL, Khan MSA, Siddiqui Z, Hossain M, Dewey KG. Provision of pre- and postnatal nutritional supplements generally did not increase or decrease common childhood illnesses in Bangladesh: a cluster-randomized effectiveness trial. *J Nutr* 2019;149:1271-81.
78. Adu-Afarwah S, Young RR, Lartey A, Okronipa H, Ashorn P, Ashorn U, Oaks BM, Dewey KG. Supplementation with small-quantity lipid-based nutrient supplements does not increase child morbidity in a semiurban setting in Ghana: a secondary outcome noninferiority analysis of the International Lipid-Based Nutrient Supplements (iLiNS)-DYAD randomized controlled trial. *J Nutr* 2020;150:382-93.

79. Bendabenda J, Alho L, Ashorn U, Cheung YB, Dewey KG, Vosti SA, Phuka J, Maleta K, Ashorn P. The effect of providing lipid-based nutrient supplements on morbidity in rural Malawian infants and young children: a randomized controlled trial. *Public Health Nutr* 2016;19:1893-903.
80. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.1) Available at: <http://www.who.int/vmnis/indicators/haemoglobin.pdf> Accessed on: 18 January 2019.
81. World Health Organization. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations (WHO/NMH/NHD/MNM/11.2). Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011. Available at: https://www.who.int/vmnis/indicators/serum_ferritin.pdf. Accessed on: 18 January 2019.
82. Erhardt JG, Estes JE, Pfeiffer CM, Biesalski HK, Craft NE. Combined measurement of ferritin, soluble transferrin receptor, retinol binding protein, and C-reactive protein by an inexpensive, sensitive, and simple sandwich enzyme-linked immunosorbent assay technique. *J Nutr* 2004;134:3127-32.
83. Crowell R, Ferris AM, Wood RJ, Joyce P, Slivka H. Comparative effectiveness of zinc protoporphyrin and hemoglobin concentrations in identifying iron deficiency in a group of low-income, preschool-aged children: practical implications of recent illness. *Pediatrics* 2006;118:224-32.
84. Brown KH, Rivera JA, Bhutta Z, Gibson RS, King JC, Lönnerdal B, Ruel MT, Sandröm B, Wasantwisut E, Hotz C. International Zinc Nutrition Consultative Group (IZiNCG) technical document #1. Assessment of the risk of zinc deficiency in populations and options for its control. *Food Nutr Bull* 2004;25:S99-203.
85. World Health Organization. Serum retinol concentrations for determining the prevalence of vitamin A deficiency in populations (WHO/NMH/NHD/MNM/11.3). Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011. Available at: <https://www.who.int/vmnis/indicators/retinol.pdf>. Accessed on: 18 January 2019.
86. de Pee S, Dary O. Biochemical indicators of vitamin A deficiency: serum retinol and serum retinol binding protein. *J Nutr* 2002;132:2895S-901S.
87. Pasricha SR, Atkinson SH, Armitage AE, Khandwala S, Veenemans J, Cox SE, Eddowes LA, Hayes T, Doherty CP, Demir AY, et al. Expression of the iron hormone hepcidin distinguishes different types of anemia in African children. *Sci Transl Med* 2014;6:235re3.
88. Bailey LB, Stover PJ, McNulty H, Fenech MF, Gregory JF, 3rd, Mills JL, Pfeiffer CM, Fazili Z, Zhang M, Ueland PM, et al. Biomarkers of Nutrition for Development-Folate Review. *J Nutr* 2015;145:1636S-80S.
89. Allen LH, Miller JW, de Groot L, Rosenberg IH, Smith AD, Refsum H, Raiten DJ. Biomarkers of Nutrition for Development (BOND): Vitamin B-12 Review. *J Nutr* 2018;148:1995S-2027S.
90. WHO, UNICEF Joint Monitoring Programme. Drinking Water. Available at <http://washdata.org/monitoring/drinking-water>. Accessed on: 26 August 2019.
91. WHO, UNICEF Joint Monitoring Programme. Sanitation. Available at <http://washdata.org/monitoring/sanitation>. Accessed on: 26 August 2019.

Box 1. Specification and definitions of outcome variables¹

Outcome variables	Definitions of dichotomous outcome variables
Hemoglobin (Hb; g/L)	
Anemia	Hb < 110 g/L (80)
Moderate to severe anemia	Hb < 100 g/L (80)
Plasma ferritin (µg/L)	
Iron deficiency (low plasma ferritin concentration)	Plasma ferritin < 12 µg/L (81)
Iron deficiency anemia	Plasma ferritin <12 µg/L Hb < 110 g/L (28)
Plasma soluble transferrin receptor concentration (sTfR; mg/L)	
Elevated plasma sTfR concentration	Plasma sTfR > 8.3 mg/L (82)
Erythrocyte zinc protoporphyrin concentration (ZPP; µmol/mol heme)	
Elevated ZPP	Erythrocyte ZPP > 70 µmol/mol heme (83)
Plasma zinc concentration (µg/dL)	
Low plasma zinc concentration	Plasma zinc < 65 µg/dL (84)
Plasma retinol concentration (µmol/L)	
Low retinol	Plasma retinol < 0.70 µmol/L (85)
Marginal retinol	Plasma retinol < 1.05 µmol/L (85)
Plasma retinol binding protein concentration (RBP; µmol/L)	
Low RBP	Plasma RBP < 0.70 µmol/L (86)
Marginal RBP	Plasma RBP < 1.05 µmol/L (86)

Hb, hemoglobin; RBP, retinol binding protein; sTfR, soluble transferrin receptor; ZPP, zinc protoporphyrin.

¹Plasma hepcidin concentration (ng/mL), low hepcidin (< 5.5 ng/mL) (87), plasma folate concentration (nmol/L), low folate (< 10 nmol/L) (88), plasma vitamin B12 concentration (pmol/L), low vitamin B12 (< 150 pmol/L), and depleted vitamin B12 (<221 pmol/L) (89) were also considered as outcome variables, however data were not yet available from a sufficient number of trials to be included in the present analyses.

Box 2. Potential effect modifiers

Study-level effect modifiers	Individual-level effect modifiers
<ul style="list-style-type: none"> Geographic region (WHO region: African vs. South-East Asia Region) Anemia burden (country-specific, closest in time to the study: < 60% vs. \geq 60%)¹ Malaria prevalence (country-specific, closest in time to the study: < 10% vs. \geq 10%)² Inflammation prevalence (study-specific:., elevated CRP \leq 25% and/or elevated AGP \leq 50% vs. elevated CRP > 25% and/or elevated AGP > 50%)³ Water quality (study-specific: < 75% vs. \geq 75% prevalence of improved drinking water)⁴ Sanitation (study specific: < 50% vs. \geq 50% prevalence of improved sanitation)⁵ Duration of child supplementation (study target: > 12 mo vs. \leq 12 mo) Iron dose in the SQ-LNS product (9 mg/d vs. < 9 mg/d)⁶ Child age at baseline or endline Frequency of contact for intervention delivery or outcome assessments during the study (weekly vs. monthly) Compliance (average percent compliance in LNS group \geq 80% vs. < 80%)⁷ 	<ul style="list-style-type: none"> Maternal BMI (< 20 kg/m² vs. \geq 20 kg/m²) Maternal age (< 25 y vs. \geq 25 y) Maternal education (no formal or incomplete primary vs. complete primary or greater) Child sex (female vs. male) Child birth order (first born vs. later born) Child baseline acute malnutrition (WLZ < -2 SD or MUAC < 125 mm vs. WLZ \geq -2 SD and MUAC \geq 125 mm; if MUAC not measured, WLZ < -2 SD vs. WLZ > -2 SD) Child baseline anemia status (Hb \geq 110 g/L vs. < 110 g/L); iron outcomes only Child high-dose vitamin A supplementation (receipt within six months prior to outcome assessment vs. non-receipt) Child inflammation at time of outcome assessment (CRP \leq 5 mg/L and AGP \leq 1 g/L vs. not) Household socio-economic status (< study median vs. \geq study median)⁸ Food security (moderate to severe food insecurity vs. mild to secure) Water quality (unimproved vs. improved)⁵ Sanitation (unimproved vs. improved)⁶ Season at the time of outcome assessment (rainy vs. dry)⁹

¹ Country-specific prevalence of anemia among children 6-59 months, based on national surveys (see Supplemental Table 3)

² Country-specific prevalence of malaria, based on World Malaria Report 2018 (see Supplemental Table 3) (50)

³ Elevated CRP defined as > 5 mg/L, elevated AGP defined as > 1 g/L.

⁴ study-specific prevalence (see Supplemental Table 3) (90)

⁵ study-specific prevalence (see Supplemental Table 3) (91)

⁶ study-specific (see Supplemental Tables 2 and 3)

⁷ study-specific, as reported based on a study-defined indicator (see Supplemental Table 3)

⁸ based on a study-defined, study-specific assets index

⁹ rainy vs. dry, based on study- and child-specific average rainfall during the month of measurement and two months prior (see Supplemental Methods and Supplemental Table 4)

Table 1. Characteristics of trials included in the individual participant data analysis

Country, years of study, study Name, trial design, (author date) ¹	Infant SQ-LNS Supplement		Maternal SQ-LNS Supplement	Participants, data available (n) ²			Prevalence of deficiency, control group at endline (%)	
	Age at start	Duration		Endline assessment	Hb sub-sample	MN sub-sample	Anemia (Hb < 110 g/L)	Iron deficiency (ferritin < 12 µg/L)
Bangladesh, 2012-2014, JiVitA-4, cluster RCT, longitudinal follow-up (Christian 2015, Campbell 2020)	6 mo	12 mo	N	4568	603	600	15.8 %	22.2 %
Bangladesh, 2011-2015, RDNS, cluster RCT; longitudinal follow-up (Dewey 2017, Matias 2018)	6 mo	18 mo	Y/N	2567	821	822	41.9 %	22.1 %
Bangladesh, 2012-2015, WASH-Benefits, cluster RCT, cross-sectional surveys (Luby 2018, Stewart 2019)	6 mo	18 mo	N	4824	420	390	16.1 %	35.4 %
Burkina Faso, 2010-2012, iLiNS-ZINC, cluster RCT, longitudinal follow-up (Hess 2015, Abbeddou 2017)	9 mo	9 mo	N	2647	2621	456	91.1 %	58.5 %
Burkina Faso, 2015-2017, PROMIS, cluster RCT, cross-sectional surveys (Becquey 2019)	6 mo	12 mo	N	1157	1155	0	70.1 %	
Ghana, 2004-2005, RCT, longitudinal follow-up (Adu-Afarwuah 2007, Adu-Afarwuah 2008)	6 mo	6 mo	N	194	194	167	58.3 %	56.1 %
Ghana, 2009-2014, iLiNS-DYAD-G, RCT; longitudinal follow-up (Adu-Afarwuah 2016, Adu-Afarwuah 2019)	6 mo	12 mo	Y	1113	989	304	44.9 %	
Kenya, 2012-2016, WASH-Benefits, cluster RCT, cross-sectional surveys (Null 2018, Stewart 2019)	6 mo	18 mo	N	6815	650	631	47.3 %	59.1 %
Madagascar, 2014-2016, MAHAY, cluster RCT, longitudinal follow-up (Galasso 2019, Stewart 2020)	6-11 mo	6-12 mo	Y/N	3438	1188	134	64.8 %	51.0 %
Malawi, 2011-2014, iLiNS-DYAD-M, RCT, longitudinal follow-up (Ashorn 2015)	6 mo	12 mo	Y	675	642	582	51.9 %	
Malawi, 2009-2012, iLiNS-DOSE, RCT, longitudinal follow-up (Maleta 2015 ³)	6 mo	12 mo	N	1018	326	268	72.0 %	
Mali, 2015-2017, PROMIS, cluster RCT, cross-sectional surveys (Huybregts 2019)	6 mo	18 mo	N	1927	1923	0	86.2 %	
Zimbabwe, 2013-2017, SHINE ⁴ , cluster RCT, longitudinal follow-up (Humphrey 2019; Prendergast 2019)	6 mo	12 mo	N	4347	3867	0	35.3 % ⁵	

Hb, hemoglobin; MN, micronutrient; SQ-LNS, small-quantity lipid-based nutrient supplements; RCT, randomized controlled trial.

¹The first (author date) refer to the main publication for each trial. The second refers to an additional publication specific to hematological and micronutrient status outcomes.

²Endline assessment (n) includes the number of children for whom any data were available for at least one outcome included in the IPD analyses (growth, development and/or biochemical). MN sub-sample includes the number of children for whom any data were available for at least one micronutrient status outcome, plus CRP and/or AGP such that values could be adjusted for inflammation.

³Trial is cited as Kumwenda 2014 in Das et al. (Cochrane Database of Systematic Reviews 2019)

⁴Trial was designed *a priori* to present results separately for HIV exposed and un-exposed children; thus considered as two comparisons in all analyses and the presentation of results.

⁵Data are for the HIV unexposed cohort only. The prevalence of anemia in the HIV exposed cohort was 36.8%.

Table 2. The effect of SQ-LNS on hemoglobin and micronutrient status

Outcomes	Number of participants (comparisons)	Mean difference: LNS - control (95% CI)	P value	Heterogeneity I² (p-for-heterogeneity)¹	Quality of the evidence (GRADE)
Hemoglobin (Hb), g/L ²	15398 (14)	2.77 (2.30, 3.25)	<0.001	0.72 (<0.001)	High
Outcomes	Number of participants (comparisons)	Ratio of geometric means: LNS / control (95% CI)	P value	Heterogeneity I² (p-for-heterogeneity)¹	Quality of the evidence (GRADE)
Ferritin, µg/L ²	3078 (7)	1.56 (1.48, 1.64)	<0.001	0.53 (0.072)	High
Soluble transferrin receptor (sTfR), mg/L ²	2480 (6)	0.83 (0.80, 0.85)	<0.001	0.46 (0.098)	High
Zinc protoporphyrin (ZPP), µmol/mol heme ²	1542 (4)	0.80 (0.75, 0.85)	<0.001	0.79 (0.001)	Moderate
Plasma zinc, µg/dL	1133 (3)	1.00 (0.97, 1.02)	0.734	0.00 (0.416)	Low
Retinol, µmol/L	1236 (4)	1.04 (1.00, 1.08)	0.057	0.08 (0.360)	Moderate
Retinol binding protein (RBP), µmol/L	2314 (5)	1.07 (1.04, 1.09)	<0.001	0.68 (0.017)	Moderate
Outcomes	Number of participants (comparisons)	Prevalence ratio: LNS / control (95% CI)	P value	Heterogeneity I² (p-for-heterogeneity)¹	Quality of the evidence (GRADE)
Anemia (Hb < 110 g/L) ²	15398 (14)	0.84 (0.81, 0.87)	<0.001	0.65 (<0.001)	High
Moderate to severe anemia (Hb < 100 g/L) ²	14375 (12)	0.72 (0.68, 0.76)	<0.001	0.64 (0.001)	High
Iron deficiency (ferritin < 12 µg/L) ²	3078 (7)	0.44 (0.39, 0.50)	<0.001	0.66 (0.009)	High
Iron deficiency anemia (Hb < 110 g/L, ferritin < 12 µg/L) ²	2702 (6)	0.36 (0.30, 0.44)	<0.001	0.71 (0.004)	High
Elevated sTfR (> 8.3 mg/L) ²	2480 (6)	0.64 (0.59, 0.70)	<0.001	0.73 (<0.001)	High
Elevated ZPP (>70 µmol/mol heme) ²	1542 (4)	0.70 (0.61, 0.79)	<0.001	0.00 (0.881)	Moderate
Zinc deficiency (plasma zinc < 65 µg/dL)	537 (2)	-	-	-	-
Low Vitamin A status (retinol < 0.70 µmol/L)	663 (3)	1.02 (0.62, 1.69)	0.938	0.01 (0.581)	Low
Marginal vitamin A status (retinol < 1.05 µmol/L)	1236 (4)	0.98 (0.85, 1.13)	0.829	0.35 (0.206)	Moderate
Low vitamin A status (RBP < 0.70 µmol/L)	1790 (3)	0.44 (0.27, 0.70)	0.001	0.00 (0.713)	Moderate
Marginal vitamin A status (RBP < 1.05 µmol/L)	2314 (5)	0.78 (0.70, 0.87)	<0.001	0.00 (0.765)	Moderate

Hb, hemoglobin; RBP, retinol binding protein; sTfR, soluble transferrin receptor concentration; ZPP, zinc protoporphyrin

¹ I^2 describes the percentage of variability in effect estimates that may be due to heterogeneity rather than chance. Roughly, 0.3 to 0.6 may be considered moderate heterogeneity, < 0.6 may be considered high heterogeneity. P-value from chi-squared test for heterogeneity. $P < 0.05$ indicates statistically significant evidence of heterogeneity of intervention effects beyond chance.

²Pre-specified as primary outcomes in the statistical analysis plan.

Table 3. Overview of study-level effect modification

Effect modifier	Hb	Anemia		Moderate-to-severe anemia		Ferritin	Iron deficiency		Iron deficiency anemia		sTfR	Elevated sTfR	
	MD	PR	PD	PR	PD	GMR	PR	PD	PR	PD	GMR	PR	PD
SE-Asia (vs. Africa)		(C)						C					
Moderate (vs. high) anemia burden		C			(C)								
Low (vs. high) malaria prevalence		C											
Lower (vs. higher) inflammation prevalence		C		C									
Improved (vs. unimproved) water quality ¹									C				
Improved (vs. unimproved) sanitation ¹									C				
Supplement duration of more than 12 mo (vs. ≤ 12 months)				C									
9 mg (vs. < 9 mg) of iron				(C)									
Weekly (vs. monthly) frequency of contact												C	
Higher (vs. lower) compliance													

MD=mean difference; GMR=geometric mean ratio; PR=prevalence ratio; PD=prevalence difference; sTfR = soluble transferrin receptor. Green indicates stronger effect in the indicated subgroup while blue indicates a stronger effect in the other subgroup. Dark color indicates p-for-interaction < 0.05; light color indicates 0.05 < p < 0.1. The letter “C” indicates that the apparent effect modification is due to the cutoff effect; when “C” is in parentheses, it is partially explained by the cutoff effect.

¹ For iron status biomarkers (ferritin and sTfR), water quality and sanitation sub-groups captured the same trials, so these characteristics are considered as a single effect modifier at the study-level. Water quality and sanitation sub-groups captured different trials for hemoglobin and anemia outcomes.

Table 4. Overview of individual-level effect modification

Effect modifier	Hb	Anemia		Moderate-to-severe anemia		Ferritin	Iron deficiency		Iron deficiency anemia		sTfR	Elevated sTfR		ZPP	Elevated ZPP		
	MD	PR	PD	PR	PD	GMR	PR	PD	PR	PD	GMR	PR	PD	GMR	PR	PD	
Higher (vs. lower) maternal BMI										C							
Older (vs. younger) mother																	
Higher (vs. lower) maternal education																	C
Female (vs. male) child		C															
Later-born (vs. first-born) child					(C)												
Acutely (vs. non-acutely) malnourished																	
Anemic (vs. non-anemic)																	
Received (vs. did not receive) Vitamin A																	
No high (vs. high) AGP or CRP																	
Higher (vs. lower) SES												C	C				
Food secure (vs. insecure)																	
Improved (vs. unimproved) water quality																	
Improved (vs. unimproved) sanitation		(C)															
Rainy (vs. dry) season								C									

AGP = α -1-acid glycoprotein; BMI = body mass index; CRP = C-reactive protein; MD=mean difference; GMR=geometric mean ratio; PR=prevalence ratio; PD=prevalence difference; sTfR = soluble transferrin receptor; ZPP = zinc protoporphyrin. Green indicates stronger effect in the indicated subgroup while blue indicates a stronger effect in the other subgroup. Dark color indicates p-for-interaction < 0.05; light color indicates $0.05 < p < 0.1$. The letter “C” indicates that the apparent effect modification is due to the cutoff effect; when “C” is in parentheses, it is partially explained by the cutoff effect.

Figure Legends

Figure 1: Study flow diagram

Figure 2: Forest plot of the effect of SQ-LNS on anemia prevalence

Figure 3: Forest plot of the effect of SQ-LNS on prevalence of iron deficiency (ferritin < 12 $\mu\text{g/L}$)

Figure 4: The effect of SQ-LNS provided to children 6-24 months of age compared with a control on (A) hemoglobin concentration, (B) anemia prevalence, (C) moderate-to-severe anemia prevalence, (D) ferritin concentration, (E) iron deficiency, (F) iron deficiency anemia, (G) soluble transferrin receptor concentration, and (H) elevated soluble transferrin receptor, stratified by study-level characteristics. Due to the limited number of studies, we were unable to examine study-level effect modification on all outcomes for all potential modifiers of interest. GMR, ratio of geometric means, MD, mean difference, PR, prevalence ratio, p-diff, p value for the difference in the effect of SQ-LNS between the two levels of the effect modifier.

Figure 5: The effect of SQ-LNS provided to children 6-24 months of age compared with a control on (A) hemoglobin concentration, (B) anemia prevalence, (C) moderate-to-severe anemia prevalence, (D) ferritin concentration, (E) iron deficiency, (F) iron deficiency anemia, (G) soluble transferrin receptor concentration, and (H) elevated soluble transferrin receptor, stratified by individual-level maternal, child and household characteristics. For some biomarkers of micronutrient status, we were unable to generate pooled estimates for effect modification by certain potential individual-level effect modifiers due to an insufficient number of comparisons. GMR, ratio of geometric means, MD, mean difference, PR, prevalence ratio, p-for-interaction, p value for the interaction indicating the difference in effects of SQ-LNS between the two levels of the effect modifier.

Supplemental Tables

Supplemental Table 1: Characteristics of trials included in the individual participant data analysis, outcomes assessed and the analytic contrasts in which they were included

Supplemental Table 2: Amount of SQ-LNS provided (g/day) and nutrient value (per daily ration)

Supplemental Table 3: Descriptive information on potential study-level effect modifiers, by trial

Supplemental Table 4: Descriptive information on potential individual-level effect modifiers, by trial

Supplemental Table 5: Description of biochemical assessments

Supplemental Table 6: Biomarker outcomes at endline among control groups, by trial

Supplemental Table 7: Risk of bias assessment in each trial

Supplemental Table 8: Overview of individual-level effect modification for zinc and vitamin A

Supplemental Figures

Supplemental Figure 1: Summary risk of bias as a percentage of all included studies

Supplemental Figure 2: Sensitivity analyses of main effects of SQ-LNS on biochemical outcomes

Supplemental Figure 3: Forest plots for all main effects of SQ-LNS on biochemical outcomes

Supplemental Figure 4: Forest plots for effects of SQ-LNS on biochemical outcomes stratified by study-level effect modifiers

Supplemental Figure 5: Sensitivity analyses of effect modification of SQ-LNS on biochemical outcomes by study-level effect modifiers

Supplemental Figure 6: Forest plots for effects of SQ-LNS on biochemical outcomes stratified by individual-level maternal and child effect modifiers

Supplemental Figure 7: Forest plots effects of SQ-LNS on biochemical outcomes stratified by individual-level household effect modifiers

Supplemental Figure 8: Sensitivity analyses of effect modification of SQ-LNS on biochemical outcomes by individual-level effect modifiers







Figure 2: Main effect on anemia





A)


Mean difference in hemoglobin concentrations



medRxiv preprint doi: <https://doi.org/10.1101/2021.02.08.21251234>; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


B)

Anemia prevalence ratio




C)

Moderate-to-severe anemia prevalence ratio




D)

Ratio of geometric mean ferritin concentrations



E)


Iron deficiency (ferritin < 12 µg/L) prevalence ratio



medRxiv preprint doi: <https://doi.org/10.1101/2021.02.08.21251234>; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


F)

Iron deficiency anemia prevalence ratio




G)

Ratio of geometric mean soluble transferrin receptor concentrations




H)

Elevated soluble transferrin receptor prevalence ratio




A)

Mean difference in hemoglobin concentrations




B)

Anemia prevalence ratio



C)


Moderate-to-severe anemia prevalence ratio



medRxiv preprint doi: <https://doi.org/10.1101/2021.02.08.21251234>; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.


D)

Ratio of geometric mean ferritin concentrations



E)


Iron deficiency (ferritin < 12 µg/L) prevalence ratio



medRxiv preprint doi: <https://doi.org/10.1101/2021.02.08.21251234>; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


F)

Iron deficiency anemia prevalence ratio



G)

Ratio of geometric mean soluble transferrin receptor concentrations



medRxiv preprint doi: <https://doi.org/10.1101/2021.02.08.21251224>; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

H)

Elevated soluble transferrin receptor prevalence ratio

